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The following studies were included, listed with the official name of each study 
followed by a 4-letter abbreviation corresponding to genotyping files and a study 
number corresponding to Supplementary Data 1: 
 
Army Study to Assess Risk and Resilience in Servicemembers (NSS1, NSS2, 
PPDS; Supplementary Data 1 #14-16) 
 See reference for details.1 Potentially traumatic events in childhood and adult 
civilian trauma were assessed in all participants, as well as military traumatic 
experience for participants who had been deployed, using a self-administered 
questionnaire. The extent of traumatic experiences was summarized, separately, in a 
non-deployment trauma variable and a deployment trauma variable. Both continuous 
variables are summaries of frequencies of responses to each of the 11 questions 
regarding non-deployment or deployment trauma. Responses range from Never (0), 
Once (1), 2-4 Times (2), 5-9 Times (3) or More than 10 Times (4). A combination of a 
computer-administered version of the Composite International Diagnostic Interview 
(CIDI) and the Posttraumatic Stress Disorder Checklist (PCL for DSM-IV)2 were used 
to assign diagnoses of lifetime Posttraumatic Stress Disorder (PTSD) according to 
DSM-IV.3 DNA for GWAS analysis was isolated from blood. The Institutional Review 
Boards of all participating institutions approved this study. 
 
Ash Wednesday (BRYA; Supplementary Data 1 #10) 
 See reference for details.4 Potentially traumatic events were identified using 
the Recent Life Events questionnaire.5 The PTSD Checklist (PCL) was used to 
assess PTSD over the prior 4 weeks by interviews.2 Respondents were considered to 
have a diagnosis if DSM-IV criteria were met. The PCL calculates PTSD symptom 
severity, which ranged from 0 to 68, by clinical interview. For this cohort (187 Cases, 
261 Controls), the mean severity was 3.28 and the standard deviation 11.56. DNA for 
GWAS analysis was isolated from saliva. The Institutional Review Board of Western 
Sydney Area Health Service approved this study. 
 
Biological Effects of Traumatic Experiences, Treatment and Recovery (BETR; 
Supplementary Data 1 #48)  
 See reference for details.6 In total, 57 PTSD patients, 29 veteran controls 
(combat controls) and 32 civilian controls (healthy controls) were included. Patients 
were recruited from one of four outpatient clinics of the Military Mental Healthcare 
Organization, The Netherlands. Patients were included after a psychologist or 
psychiatrist diagnosed PTSD. PTSD diagnosis was confirmed using the Clinician 
Administered PTSD scale (CAPS ≥457). The Structural Clinical interview for DSM-IV 
(SCID-I8) was applied to diagnose comorbid disorders. Control participants were 
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recruited via advertisements, and the interviews (SCID and CAPS) were also applied 
to investigate PTSD symptoms and psychiatric disorders. Inclusion criteria for 
controls were no current psychiatric or neurological disorder, and no presence of 
current PTSD symptoms (CAPS ≤15). After receiving a complete written and verbal 
description of the study all participants gave written informed consent. The Medical 
Ethical Committee of the UMC Utrecht approved the study, and the study was 
performed in accordance with the Declaration of Helsinki. 
 Potentially traumatic events were identified using the Life Events Checklist for 
DSM-IV (LEC-IV).9 The CAPS for DSM-IV was used to assess PTSD over the prior 
month by trained researchers.7 The CAPS calculates PTSD symptom severity, which 
ranged from 0 to 107, by calculating the total CAPS score. For this cohort (57 Cases, 
61 Controls), the mean severity was 50.05 and the standard deviation 32.86. 
Respondents were considered to have a lifetime diagnosis if DSM-IV criteria were 
met. Respondents were considered to have a current diagnosis if DSM-IV were met 
in the previous month. The Institutional Review Board of Utrecht University Medical 
Center approved this study. 
 
Bounce Back Now (BOBA; Supplementary Data 1 #18) 
 See reference for details.10 Potentially traumatic events were identified using 
National Survey (NSA) on Adolescents PTSD module which was administered by 
trained interviewers using computer assisted telephone interview technology. The 
NSA PTSD Module assessed for exposure to five types of potentially traumatic 
events, in addition to five specific questions about the impact of the tornado (e.g., did 
the tornado cause damage to your house or property?).10,11 The NSA PTSD Module 
that was administered was used to assess PTSD since the tornado, as well as during 
any two week period in their lifetimes, and lifetime PTSD was used in the present 
analyses.11 Respondents were considered to have a lifetime diagnosis if DSM-IV 
PTSD criteria (i.e., at least one re-experiencing symptom, three avoidance 
symptoms, and two or more arousal symptoms) were met for at least a two week 
period. For this cohort, 127 individuals with lifetime PTSD were matched by sex and 
race/ethnicity with 127 controls who did not meet criteria for lifetime PTSD. DNA for 
GWAS analysis was isolated from saliva collected via Oragene kits. The Institutional 
Review Board of the Medical University of South Carolina approved this study. 
 
Childhood Trauma Study (QIMR; Supplementary Data 1 #30) 
 See references for details.12,13 Potentially traumatic events were identified 
using a semi-structured psychiatric diagnostic telephone assessment that included 
questions on childhood maltreatment.14 Lifetime DSM-IV PTSD (binary measure) was 
assessed using a modified version of the measure from the National Comorbidity 
Survey by telephone interviewers trained by an experienced clinical psychologist.15 
For respondents who had experienced more than one potentially traumatic event, 
assessment of lifetime PTSD focused on the event identified by each respondent as 
most disturbing. DNA for GWAS analysis was isolated from blood. The Queensland 
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Institute of Medical Research Ethics Committee and the Washington University 
School of Medicine Human Research Protection Office approved this study. 
 
Child Trauma and Neural Systems Underlying Emotion Regulation (KMCT; 
Supplementary Data 1 #19) 
 Potentially traumatic events were identified using The UCLA PTSD Reaction 
Index,16 the Childhood Experiences of Care and Abuse Interview,17 and the 
Childhood Trauma Questionnaire.18 The Clinician Administered PTSD Scale for 
Children19 was used to assess both lifetime and current PTSD by trained clinical 
interviewers.17 Children and a parent or guardian completed the interview, and an or 
rule was used to assign diagnoses. Respondents were considered to have a 
diagnosis if DSM-5 criteria were met. Respondents were considered to have a 
current diagnosis if DSM-5 criteria were met. The UCLA PTSD Reaction Index16 
calculates PTSD symptom severity. Children and a parent or guardian each 
completed this measure, and we used the highest score from either the child or 
parent, which ranged from 0 to 67 in our sample. For this cohort (133 Cases, 122 
Controls), the mean severity was 17.57 and the standard deviation 17.94. DNA for 
GWAS analysis was isolated from saliva. The Institutional Review Board of the 
University of Washington approved this study. 
 
CHOICE (FEEN; Supplementary Data 1 #37) 
 See reference for details.20-29 Potentially traumatic events were identified using 
the standard trauma interview.30 The PTSD Symptom Scale – Interview (PSS-I) was 
used to assess PTSD over the prior two weeks for the trauma of interest by 
postdoctoral or graduate level assessors trained to reliability8. The Structured Clinical 
Interview (SCID-IV) was used to assess lifetime PTSD (not current) for a trauma not 
the focus of treatment by postdoctoral or graduate level assessors trained to 
reliability.31 Respondents were considered to have a current diagnosis if on the PSS-I 
they met symptom-level DSM-IV diagnostic criteria. The PSS-I also provides PTSD 
symptom severity, with a range from 0 to 51. For this cohort (104 Cases), the mean 
severity was 32.63 and the standard deviation 4.87. DNA for GWAS analysis was 
isolated from blood. The Institutional Review Board of University Hospitals approved 
this study. 
 
Cohen Veterans Center Study (COM1; Supplementary Data 1 #50) 
 See reference for details.32-34 This is a multi-site study that ran through 
NYUMC and Stanford University and Palo Alto VAMC. The VA Palo Alto Health Care 
System has an affiliation with Stanford University School of Medicine. Dr. Charles 
Marmar is the overall PI for this study. 
 Potentially traumatic events were identified using clinical interview that was 
administered by a licensed psychologist.35 The CAPS was administered by clinicians 
to assess PTSD for two time periods: the preceding 30 days and a one-month period 
6 
 
in the past when symptoms were the worst, by respondent’s subjective account.7 The 
CAPS calculates PTSD symptom severity by summing the scores for all items, which 
ranged from 0 to 80 in the full range and ranged from 0 to 56 in this dataset (in the 
Cohen Veterans Center study). For this cohort (232 Cases, 802 Controls), the mean 
severity was 12.14 and the standard deviation 11.85. Respondents were considered 
to have a current diagnosis if DSM-5 criteria were met in the preceding 30 days. 
Respondents were considered to have a lifetime diagnosis if DSM-5 criteria were met 
in the month when symptoms were the worst. The Institutional Review Board of 
NYUMC and Stanford University approved this study. 
 
Cortical Excitability: Biomarker and Endophenotype in Combat Related PTSD 
(WANG; Supplementary Data 1 #59)  
 Potentially traumatic events were identified using CAPS Life Event Checklist. 
The CAPS was used to assess PTSD over the prior 4 weeks, by research 
coordinators/interviewers.7 Respondents were considered to have a diagnosis if 
CAPS>45. Respondents were considered to have a current diagnosis if CAPS>45. 
The CAPS calculates PTSD symptom severity, which ranged from 0 to 123 out of a 
possible 136, by interview.7 For this cohort (208 Cases, 87 Controls), the mean 
severity of cases was 76.22 and the standard deviation was 16.85. DNA for GWAS 
analysis was isolated from whole blood. The Institutional Review Board of Medical 
University of South Carolina approved this study. 
 
Danish military study (DAMI; Supplementary Data 1 #28)  
 Potentially traumatic events were identified with 11 single items listing 
potentially traumatic events occurring during deployment. A scale developed for the 
Danish military, the PRIM-PTSD, was used to assess PTSD-symptoms over the 
previous 3 months36. The PRIM-PTSD calculates PTSD symptom severity, with a 
possible range of 12-48. For this cohort (462 Cases, 2019 Controls after quality 
control), the mean severity was 17.97 and the standard deviation 5.92. PTSD cases 
were defined as having a PRIM-PTSD score at or above 25, equaling a score of 44 
on the PTSD Checklist. DNA for GWAS analysis was isolated from neonatal blood 
spots. The Regional Committee on Health Research Ethics, Region Zealand, 
approved this study. 
 
Danish iPSYCH PTSD samples (DAIP; Supplementary Data 1 #29) 
 See reference for details.37-39 The Danish iPSYCH PTSD samples were 
identified for analysis using infrastructure provided by the iPSYCH project.40 The 
iPSYCH project is a case cohort study, drawing individuals born in Denmark between 
1981 and 2005, and obtaining all cases diagnosed with six disorders plus 30,000 
random individuals from the same population cohort as controls. PTSD was not one 
of the original six diagnoses within iPSYCH, but cases were identified in linked 
records (i.e. PTSD diagnosis comorbid with one of the six ascertained disorders or 
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PTSD diagnosis in one of the 30,000 iPSYCH “controls”). PTSD was assessed via 
clinician diagnosis according to ICD-10 (F43.1), as obtained from either of two 
registers in Denmark: the Danish Psychiatric Central Research Register and/or the 
Danish National Patient Register. Diagnoses in the registers are for current disorders 
(i.e. not lifetime). PTSD severity was not available. DNA for GWAS analysis was 
isolated from bloodspots from the Danish Neonatal Screening Biobank hosted by the 
Statens Serum Institut, as described previously.38,39 The study was approved by the 
Regional Danish Ethics Committee and the Danish Data Protection Agency. 
 
DCS Rothbaum Study (DCSR; Supplementary Data 1 #38) 
 See reference for details.41,42 The authors examined the effectiveness of 
virtual reality exposure augmented with D-cycloserine or alprazolam, compared with 
placebo, in reducing PTSD due to military trauma. 
After an introductory session, five sessions of virtual reality exposure were 
augmented with D-cycloserine (50 mg) or alprazolam (0.25 mg) in a double-blind, 
placebo-controlled randomized clinical trial for 156 Iraq and Afghanistan war veterans 
with PTSD.43 
 PTSD symptoms significantly improved from pre- to posttreatment across all 
conditions and were maintained at 3, 6, and 12 months. There were no overall 
differences in symptoms between D-cycloserine and placebo at any time. Alprazolam 
and placebo differed significantly on the Clinician-Administered PTSD Scale (CAPS) 
score at posttreatment and PTSD diagnosis at 3 months posttreatment; the 
alprazolam group showed a higher rate of PTSD (82.8%) than the placebo group 
(47.8%).7 Between-session extinction learning was a treatment-specific enhancer of 
outcome for the D-cycloserine group only. At posttreatment, the D-cycloserine group 
had the lowest cortisol reactivity and smallest startle response during virtual reality 
scenes. 
 A six-session virtual reality treatment was associated with reduction in PTSD 
diagnoses and symptoms in Iraq and Afghanistan veterans, although there was no 
control condition for the virtual reality exposure. There was no advantage of D-
cycloserine for PTSD symptoms in primary analyses. In secondary analyses, 
alprazolam impaired recovery and D-cycloserine enhanced virtual reality outcome in 
patients who demonstrated within-session learning. D-cycloserine augmentation 
reduced cortisol and startle reactivity more than did alprazolam or placebo, findings 
that are consistent with those in the animal literature. 
 
Defining Essential Features of Neural Damage (DEFE; Supplementary Data 1 
#12) 
 See reference for details.44,45 Potentially traumatic events were identified using 
the Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV), the Combat Exposure 
Scale (CES), and items from the Deployment Risk and Resilience Inventory 
(DRRI).7,35,46 The CAPS-IV was also used to assess PTSD currently (over the prior 2 
weeks) and over the lifetime by trained interviewers.7 The CAPS-IV calculates PTSD 
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symptom severity, which ranged from 0 to 120. For this cohort (88 Cases, 62 
Controls), the mean severity was 31.43 and the standard deviation 25.01. 
Respondents were considered to have a lifetime diagnosis if they met DSM-IV 
criteria for PTSD (measured using CAPS-IV) either current or past. Respondents 
were considered to have a current diagnosis if they met DSM-IV criteria for PTSD 
(measured using CAPS-IV) at the time of the assessment. The Institutional Review 
Board of the Minneapolis VA Health Care System approved this study. 
 
Detroit Neighborhood Health Study (DNHS, ADNH; Supplementary Data 1 #4 
and #45) 
 See reference for details.47 Potentially traumatic events (PTEs) were identified 
using a list of 19 PTEs.48 The PTSD Checklist-Civilian (PCL-C) was used to assess 
PTSD over the lifetime by self-report during structured telephone interviews by 
referencing two traumatic events; one the respondent regarded as the worst and a 
second randomly selected event from the list of remaining PTEs (if the respondent 
experienced more than one traumatic event).49 Respondents were considered to 
have a diagnosis if all six DSM-IV criteria were met for either the worst or random 
event. Additional questions assessed the timing, duration, severity or illness, and 
disability resulting from symptoms. PTSD symptom severity, which ranged from 17 to 
85, was assessed by summing the respondents’ ratings of the 17 post-traumatic 
symptoms on a scale indicating the degree to which the respondent was bothered by 
a particular symptom as a result of the worst trauma, ranging from 1 (not at all) to 5 
(extremely). All DNHS participants, include N = 2081, of which cases N = 408 and 
controls N=1532. DNA for GWAS analysis was isolated from peripheral blood or 
saliva. The Institutional Review Board at the University of Michigan and University of 
North Carolina Chapel Hill approved this study. 
 
Drakenstein Child Health Study - South African sample (SAFR; Supplementary 
Data 1 #3)  
 See reference for details.50 51 52 The modified PTSD Symptom Scale (PSS) 
was used to assess PTSD.31 Specifically, the re-experiencing symptom cluster was 
considered met if the sum of reported symptoms totaled greater than or equal to 1; 
the avoidance/emotional numbing reported symptoms were greater than or equal to 
3; and increased arousal cluster reported symptoms were greater than or equal to 2. 
Participants who scored above threshold in each of the clusters and had symptom 
duration for at least 1 month were classified as PTSD cases. The Faculty of Health 
Sciences human research ethics committee of the University of Cape Town (UCT) 
approved this study. 
 
EA CRASH (EACR; Supplementary Data 1 #42) 
 See reference for details.53 European American individuals were enrolled in 
the Emergency Department within 24 hours following motor vehicle collision (MVC) 
trauma/stress.54 The Impact of Events Scale-Revised (IES-R) was used to assess 
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PTS symptom severity over the past week by research assistants 1 year following 
MVC.54 Respondents were considered to have a diagnosis if they scored 33 or higher 
on the IES-R questionnaire. The IES-R inventory calculates PTS symptom severity, 
which ranged from 0 to 88, by scoring a participant’s answers to 22 questions on a 
scale of 0-4 about symptoms of avoidance, intrusions, and hyperarousal. For this 
cohort (88 Cases, 276 Controls), the mean PTS symptom severity was 19.2 and the 
standard deviation was 18.4, measured 1-year after the MVC. DNA for GWAS 
analysis was isolated from blood collected in DNA PAXgene tubes. The Institutional 
Review Board of The University of North Carolina at Chapel Hill approved this study. 
 
Family Study of Cocaine Dependence and Collaborative Genetic Study of 
Nicotine Dependence (FSCD, COGA, COGB; Supplementary Data 1 #7-9) 
 See references for details.55,56 A module from the Diagnostic Interview 
Schedule for DSM-IV (DIS-IV),57 a structured assessment that evaluated the 
presence or absence of psychiatric disorders according to the DSM-IV58 criteria was 
used to evaluate PTSD in a sample of 471 cases and 3,568 controls. A history of 
fifteen specific traumatic events were queried including rape or sexual assault, 
assaultive violence (e.g., shot, stabbed), witnessing trauma to others, and non-violent 
trauma (e.g., serious accident, sudden death of a loved one). The traumatic events 
were assessed using closed-ended questions (e.g., Have you ever been raped or 
sexually assaulted?) with nominal response options (i.e., Yes or No). Participants 
were asked to select the most distressing event and were subsequently evaluated for 
symptoms of PTSD. A diagnosis of PTSD was dependent on Criterion A, which 
required intense fear, helplessness, or horror in association with the most distressing 
event. Interview data were checked for consistency by a senior editor and entered 
into a computerized data file. Lifetime psychiatric diagnoses were made by a 
computer algorithm that analyzed responses to the interview using DSM-IV criteria. 
The Washington University School of Medicine IRB approved the studies. 
 
Fort Campbell study (FTCB; Supplementary Data 1 #52)  
 Fort Campbell is a United States Army installation located astride the 
Kentucky-Tennessee border between Hopkinsville, Kentucky, and Clarksville, 
Tennessee. Fort Campbell is home to the 101st Airborne Division and the 160th 
Special Operations Aviation Regiment. One thousand, seven hundred and ninety-
three (N=1793) active duty members of the Army’s 101st Airborne Division who 
deployed to Afghanistan participated in the study. Each participant was evaluated 
one-three times at the Fort Campbell U.S. Army military installation. The first 
evaluation took place prior to deployment in January-February, 2014, the second 
evaluation took place 3 days upon return from deployment and the third evaluation 
occurred 90-180 days upon return from deployment. 
 Potentially traumatic events were identified using self-report questionnaire that 
included PCL 5.59 The PTSD Checklist for DSM 5 (PCL-5) was used to assess PTSD 
during each phase of the study (pre-deployment, 3 days post deployment and 90-180 
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days post deployment).59 The PCL-5 score calculates PTSD symptom severity by 
summing the scores for all items, which ranged from 0 to 80 in the full range and 
ranged from 0 to 75 in this dataset. For this cohort (114 Cases, 1624 Controls), the 
mean severity was 6.81 and the standard deviation 11.24. Respondents were 
considered to have a current diagnosis if PCL5 score is at least 33. The Institutional 
Review Board of NYUMC and HARPO (DoD IRB) approved this study. 
 
Genetic and Environmental Predictors of Combat-Related PTSD (STRO; 
Supplementary Data 1 #35) 
 See reference for details.60 Subjects in this study were included from a larger 
STRONG STAR pre-/post-deployment study of deploying soldiers from Fort Hood in 
Killeen, Texas. The data included in this analysis are from the pre-deployment 
assessment. Potentially traumatic events were identified using the Life Events 
Checklist (LEC).9 The PTSD Checklist–Military Version (PCL-M) was used to assess 
PTSD over the prior month by self-repor.2 Subjects were considered to have a 
current diagnosis if the total score on the PCL was  50 and classified as a control if 
their PCL total score was < 50. In addition, both cases and controls were required to 
report having directly experienced or witnessing a traumatic event on the LEC. Based 
on these criteria, N=607 subjects were classified as having current PTSD and 
N=3,390 were classified as controls. DNA for GWAS analysis was isolated from 
blood. The Institutional Review Board of University of Texas Health Science Center 
at San Antonio approved this study. 
 
Genetic Risk for PTSD (YEHU; Supplementary Data 1 #56) 
 See reference for details.61,62 Potentially traumatic events were identified using 
the CAPS, SCID, MINI, and the Life Events Checklist.7,9,63,64 The CAPS, SCID, and 
MINI were used to assess PTSD during the past month or over the prior lifetime by a 
PhD level clinical psychologist.7,63,64 Respondents were considered to have a 
diagnosis if at least one Criterion B symptom, at least three Criterion C symptoms, at 
least two Criterion D symptoms, and Criterion A, E, and F (CAPS), J1, J2, and J3 are 
coded “yes”, at least three or more J4 questions are coded “yes”, at least two J5 
answers are coded “yes”, and J6 is coded “yes” (MINI), and/or subject experienced a 
traumatic event and adverse consequences were experienced, both A criteria were 
coded 3, at least one B criteria was coded 3, at least three C criteria were coded 3, 
and at least two D criteria were coded 3 (SCID). Respondents were considered to 
have a current diagnosis if criteria for PTSD diagnosis were met within the past 
month. The CAPS calculates PTSD symptom severity, which ranged from 0 to 136. 
For this cohort (123 cases, 43 controls), the mean severity was 80.19 and the 
standard deviation 2.23. DNA for GWAS analysis was isolated from whole blood. The 
Institutional Review Board of James J. Peters VA Medical Center and Icahn School 




Genetics of Posttraumatic Stress Disorder/Substance Use Disorder 
Comorbidity (KSUD; Supplementary Data 1 #17) 
 See reference for details.65 Potentially traumatic events were identified using 
the Life Event Checklist for DSM-5 (LEC-5).66 The self-report PTSD Checklist for 
DSM-5 (PCL-5)59 was used to assess PTSD symptoms over the prior month. The 
PCL-5 contains 20 items which summed provide a measure of PTSD symptom 
severity (scores range from 0 to 80). For this cohort (137 Cases, 106 Controls), the 
mean severity was 40.57 and the standard deviation 20.96. Respondents were 
considered to have a current diagnosis if total symptom severity was at or above 38. 
The Institutional Review Board of Kent State University approved this study. 
 
GMRF-QUT (GMFR; Supplementary Data 1 #55)  
 See reference for details.67 Potentially traumatic events were identified using 
Criterion A event. The Clinician Administered PTSD Scale for DSM 5 (CAPS-5) was 
used to assess PTSD over the prior 2 weeks and lifetime by clinical psychologists.68 
Respondents were considered to have a current diagnosis if CAPS-5 criteria were 
met. The CAPS-5 calculates PTSD symptom severity, which ranged from 0 to 56. For 
this cohort (100 Cases, 124 Controls), the mean severity was 9.63 and the standard 
deviation 10.05. DNA for GWAS analysis was isolated from peripheral blood. Ethics 
approval for the project was obtained from the Department of Veterans’ Affairs, 
Greenslopes Private Hospital, and Queensland University of Technology Human 
Research Ethics Committees. This study was carried out in accordance with The 
Code of Ethics of the World Medical Association (Declaration of Helsinki). 
 
Genetics Research and the Childbearing Year (GRAC; Supplementary Data 1 
#54) 
 See reference for details.69 A total of 29 potentially traumatic events were 
identified using the Life Stressor Checklist70. PTSD symptoms were assessed using 
the National Women’s Study PTSD Module (NWS-PTSD), a widely used scale 
designed for use by lay interviewers, that consists of 20 items that assess DSM-IIl-R 
PTSD Criteria B, C, and D symptoms. The NWS-PTSD was performed by trained lay 
interviewers using computer-aided telephone interviewing and epidemiological 
methods (forced choice yes or no).71,72 Respondents were considered to have a 
diagnosis if lifetime DSM-IV PTSD criteria were met. Respondents were considered 
to have a current diagnosis if past month DSM-IV criteria were met. The NWS-PTSD 
assesses the number of PTSD symptoms endorsed, which ranged from 0 to 17. For 
this cohort (140 Cases, 138 Controls), the mean PTSD symptom count (out of 17 
possible symptoms) was 6.4 and the standard deviation 5.5. DNA for GWAS analysis 
was isolated from saliva (Oragene tube). The Institutional Review Board of the 
University of Michigan approved this study. 
 
Grady Trauma Project (EGHS, GTPC; Supplementary Data 1 #44 and #47) 
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 See reference for details.73 The modified PTSD Symptom Scale (PSS), a 
psychometrically valid 17-item self-report scale assessing PTSD symptomatology 
over the prior 2 weeks, was used to assess PTSD.74 Consistent with prior literature, 
the PSS frequency items (0 indicates not at all to 3 indicates ≥5 times a week) to 
obtain a continuous measure of PTSD symptom severity ranging from 0 to 51. For 
this sample, the PSS frequency items had standardized α=.90 (mean [SD], 13.81 
[11.96]). No clearly established PSS cutoff score for PTSD diagnosis has been 
established; however, DSM-IV criteria for PTSD can be applied to PSS frequency 
items to create a proxy variable for PTSD diagnostic status. The Institutional Review 
Boards of Emory University School of Medicine and Grady Memorial Hospital 
approved this study. 
 
Growing Up Today Study (GUTS; Supplementary Data 1 #21) 
See reference for details.75 Potentially traumatic events were identified using 
the Brief Trauma Questionnaire,76 plus questions on stalking and intimate partner 
violence (specific events queried included: witness an attack, get attacked, disaster, 
serious accident, attack on family member, stalked, family member killed in violence, 
served in war zone/saw war casualties, serious injury to self, physical intimate 
partner violence, sexual intimate partner violence). Breslau’s Short Screening Scale 
for DSM-IV PTSD was used to assess PTSD over the lifetime by self-report of 
symptoms.77 Respondents were considered to have a lifetime diagnosis if they 
reported experiencing 4 or more symptoms. Current diagnosis was not assessed. 
Breslau’s Short Screening Scale for DSM-IV PTSD calculates PTSD symptom 
severity, which ranged from 0 to 7, by counting the number of symptoms. For this 
cohort (312 Cases, 312 Controls), the severity was mean=2.63, SD=2.31 (cases: 
mean=4.93, SD=0.94; controls: mean=0.34, SD=0.47). DNA for GWAS analysis was 
isolated from saliva. The Institutional Review Board of Brigham and Women’s 
Hospital approved this study. 
 
Injury and Traumatic Stress Consortium (INTR; Supplementary Data 1 #27) 
 Subjects were participants in studies of the INTRuST Consortium, some of 
which are cited.78-80 Potentially traumatic events were identified using the Life Events 
Checklist for DSM-IV (LEC)2 and/or the Deployment Risk and Resilience inventory 
(DRRI).81 The PTSD Checklist for DSM-IV (PCL)2 was used to indicate a likely 
diagnosis of PTSD (or healthy control status); in some cases, this diagnosis was 
corroborated by the Clinician-Administered PTSD Scale (CAPS).7,82 The PCL was 
used as an indicator of PTSD symptom severity, which ranged from 17-85. DNA for 
GWAS analysis was isolated from whole blood. The Institutional Review Boards of 
UCSD (the Coordinating Center) and all the participating institutions approved this 
research. 
 
IVS (BRYA; Supplementary Data 1 #10) 
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 See reference for details.83 Potentially traumatic events were identified using 
the Recent Life Events questionnaire.5 The Clinician Administered PTSD Scale 
(CAPS) was used to assess PTSD over the prior 4 weeks by psychologist 
interviewers.7 Respondents were considered to have a current diagnosis if DSM-IV 
were met. The CAPS calculates PTSD symptom severity, which ranged from 0 to 
136, by clinical assessment. For this cohort (90 Cases, 312 Controls), the mean 
severity was 25.10 and the standard deviation 23.98. DNA for GWAS analysis was 
isolated from saliva. The Institutional Review Board of Western Sydney Area Health 
Service approved this study. 
 
Marine Resiliency Study (MRSC, BAKE; Supplementary Data 1 #1 and #57)  
 See reference for details.84,85 Participants were recruited from two studies 
including military personnel: (1) the Marine Resiliency Study, a prospective PTSD 
study with longitudinal follow-up (pre- and post-exposure to combat stress) of U.S. 
Marines bound for deployment to Iraq or Afghanistan, and (2) a cross-sectional study 
involving a cohort of combat-exposed active duty or previously deployed service 
members (CAVC), including PTSD cases and controls with comparable psychosocial 
and clinical phenotypes. PTSD was diagnosed up to 3 times, once before 
deployment and 3 and/or 6 month post deployment. Post-traumatic stress (PTS) 
symptoms were assessed using a structured diagnostic interview, the Clinician 
Administered PTSD Scale (CAPS), and PTSD diagnosis followed the DSM-IV 
criteria.7 All participants included in this study met the DSM-IV criteria A1 event. For 
participants assessed at multiple timepoints, the timepoint with the highest CAPS 
score was used. Genomic DNA was prepared from blood leukocytes and genotyping 
was carried out by Illumina (http://www.illumina.com/) using the HumanOm-
niExpressExome (HOEE) array with 951,117 loci and by RUCDR 
(http://www.rucdr.org) using the HOEE array with 967,537 loci. The study was 
approved by the University of California San Diego Institutional Review Board, and all 
participants pro-vided written informed consent to participate. 
 
McLean Trauma Sample (TEIC; Supplementary Data 1 #39) 
 The McLean Trauma Sample consists of three separate studies lead by Drs. 
Milissa Kaufman and Martin Teicher. See references for details.86-88 The first study 
was conducted at McLean Hospital’s Developmental Biopsychiatry Research 
Program (PI: Martin Teicher, MD, PhD) entitled “Sensitive Periods, Brain 
Development and Depression Study”. The group aimed to test the hypothesis that 
there are discrete sensitive periods when exposure to abuse or loss is maximally 
associated with risk for developing psychiatric disorders, specifically major 
depression and that risk for developing depression coincided with exposure to abuse 
during sensitive periods of hippocampal and prefrontal cortex vulnerability. These 
hypotheses were tested in a sample of 517 individuals (20-25 years of age) recruited 
from the community. Degree and timing of developmental exposure to abuse and 
loss across each childhood stage was quantified retrospectively using the 
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Maltreatment and Abuse Chronology of Exposure (MACE) scale,89 as well as 
Traumatic Antecedent Interview,90 Childhood trauma Questionnaire91 and Adverse 
Childhood Experiences scale.92 Lifetime and current psychopathology including 
PTSD was assessed by trained psychologists, psychiatrists and clinical nurse 
specialists, using the Structured Clinical Interview for DSM-IV-TR.93 Respondents 
were considered to have a current diagnosis if DSM-IV-TR criteria were met in the 
preceding 30 days. 
 The second study was also conducted at McLean Hospital’s Developmental 
Biopsychiatry Research Program (PI: Martin Teicher). The key aims of the project 
were to test in a prospective study whether neurobiological correlates such as T2-
relaxation time in dorsolateral prefrontal and anterior cingulate cortex and a large 
cerebellar lingual size can predict degree of drug and alcohol use in individuals with 
histories of childhood abuse and neglect, with an emphasis on sensitive periods of 
maximal exposure. These hypotheses were tested in a sample of 157 individuals (18-
19 years of age) recruited from the community. Structured Clinical Interviews for 
DSM-IV (SCID-IV) Axis I and II psychiatric disorders were used for diagnoses.93 
Mental health professionals (psychiatrists, Ph.D. psychologists, clinical nurse 
specialists) performed all the interviews and psychological assessments. In addition 
to the Maltreatment and Abuse Chronology of Exposure (MACE) scale,89 the 100-
item semi-structured Traumatic Antecedents Interview90 was also used to assess 
maltreatment history, as well as the Childhood Trauma Questionnaire91 and the 
Adverse Childhood Experience score.92 PTSD was diagnosed using the SCID-IV-TR 
and the CAPS.7 
 The third study was conducted at McLean’s Dissociative Disorders and 
Trauma Research Program (PI: Milissa Kaufman, MD, PhD) entitled “Evaluating the 
Neurobiological Basis of Traumatic Dissociation in a Cross-Diagnostic Sample of 
Women with Histories of Childhood Abuse and Neglect”. Patients were recruited from 
inpatient and partial/residential treatment programs at McLean Hospital as part of a 
larger study on trauma-related dissociation comprised of diagnostic interviews, self-
reports, neuropsychological testing, and neuroimaging protocols. All 
individuals endorsed a history of childhood trauma exposure, as assessed by the 
Traumatic Events Interview and Childhood Trauma Questionnaire. All participants 
also met criteria for DSM-5 PTSD as assessed by the Clinician-Administered PTSD 
Scale for DSM-5. 
 The Institutional review Board of McLean Hospital approved all studies. All 
saliva samples were collected using Oragene DNA collection kits (DNA Genotek) 
according to the instructions of the manufacturer. 
 
Mid-Atlantic Mental Illness Research Education and Clinical Center the study of 
Post-Deployment Mental Health Study (MIRE; Supplementary Data 1 #26) 
 See reference for details of the study of Post-Deployment Mental Health 
(1,308 cases, 1,914 controls).94,95 PTSD was diagnosed using the Structured Clinical 
Interview for DSM-IV Disorders (SCID) administered by trained interviewers.8 In 
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accordance with the DSM-IV, PTSD consisted of three symptom clusters. These 
included re-experiencing symptoms (B symptoms), avoidance and numbing 
symptoms (C symptoms) and hyperarousal symptoms (D symptoms). Total PTSD 
symptoms and symptom clusters (B, C, or D) were measured using the Davidson 
Trauma Scale for all veterans, including individuals with current PTSD diagnosis and 
controls. The research was reviewed and approved by the Institutional Review 
Boards at the Salisbury, NC VA, Hampton, VA VA, Richmond, VAVA, Durham, NC 
VA and Duke University Medical Centers. 
 
National Centre for Mental Health (NCMH; Supplementary Data 1 #41)  
 See www.ncmh.info for details. Potentially traumatic events were identified by 
participant self-report. The Trauma Screening Questionnaire (TSQ) was used to 
assess PTSD over the prior 2 weeks by self-report.96 Respondents were considered 
to have a current diagnosis if a score of 6 or more was obtained. The TSQ calculates 
PTSD symptom severity, which ranged from 0 to 10, by self-report. For this cohort 
(631 Cases, 653 Controls), the mean severity was 5.32 and the standard deviation 
3.47. DNA for GWAS analysis was isolated from blood or saliva. The study was given 
a favorable ethical opinion by Wales Research Ethics Committee (REC) 2. 
 
National Health and Resilience in Veterans Study (NHRV; Supplementary Data 
1 #13) 
 See reference for details.97 Potentially traumatic events were identified using 
the Trauma History Screen.98 The PTSD Checklist-Specific (PCL-S) was used to 
assess both lifetime and past-month PTSD symptoms related to respondent’s ‘worst’ 
traumatic event over their lifetimes by survey.2 Respondents were considered to have 
screen positive for PTSD if their PCL-S score was ≥50. The PCL-S calculates PTSD 
symptom severity, which ranged from 17 to 85, by self-report. For this cohort (95 
Cases, 1490 Controls), the mean PCL-S severity score was 26.9 and the standard 
deviation 11.3. DNA for GWAS analysis was isolated from saliva. The Human 
Subjects Subcommittee of VA Connecticut Healthcare System approved this study. 
 
NIU Trauma Study (NIUT; Supplementary Data 1 #40) 
 See reference for details.99,100 Potentially traumatic events were identified 
using the Traumatic Life Events Questionnaire and 12 questions regarding level of 
exposure to the campus shooting.101 The Distressing Events Questionnaire was used 
to assess PTSD immediately following the mass shooting (average 3.2 weeks) by 
self-report.102 Respondents were considered to have a diagnosis if their DEQ score 
was ≥ 18. The DEQ calculates PTSD symptom severity, which ranged from 0 to 66, 
by self-report. For this cohort (280 Cases, 411 Controls), the mean severity was 
16.49 and the standard deviation 12.35. DNA for GWAS analysis was obtained from 
204 of the PTSD cases and was isolated from saliva. The Institutional Review Board 




Nurses Health Study II (NHS2; Supplementary Data 1 #5) 
 See reference for details.103 Participants identified stressful events they had 
experienced from a list of 25 events used in diagnostic interviews, 104, 28,105-107 and 
PTSD was assessed in relation to participants’ self-selected worst stressful event. 
Participants were cued to think of the period following the event during which 
symptoms were most frequent and intense. They were asked whether they had ever 
been bothered by each of 17 symptoms and rated each symptom on a Likert-style 
scale (1: “not at all” to “5: extremely”).108 Additional questions assessed the other 
three DSM-IV criteria: intense fear, horror, or helplessness in response to the event 
(Criterion A2), symptom duration of at least one month (Criterion E), and clinically 
significant impairment in functioning due to symptoms (Criterion F)104. Based on the 
diagnostic interview, we created two lifetime PTSD phenotypes as follows. 
 To meet criteria for lifetime PTSD diagnosis, respondents must have endorsed 
experiencing one or more of the 5 re-experiencing symptoms, 3 or more of the 7 
avoidance/numbing symptoms, 2 or more of the 5 arousal symptoms, and criteria A2, 
E and F as defined above. In addition to the diagnostic phenotype, we analyzed 
lifetime PTSD symptom severity which was defined as the sum of the symptom 
ratings across the 17 questions. 
 The reliability of the PTSD diagnosis was assessed using a blind review of 
audiotapes from 50 interviews and the Cohen’s kappa statistic was 1.0 (perfect 
reliability).109 We assessed the validity of our identification of PTSD in a separate 
cohort, the Detroit Neighborhood Health Study, via clinical interviews among a 
random subsample of 51 participants and found excellent concordance.47 The 
Partners Human Research Committee approved this study. 
 
Nurses Health Study II (NHSY; Supplementary Data 1 #22) 
 See reference for details.110 The Nurses’ Health Study II is an ongoing cohort 
of 116,430 female nurses initially enrolled in 1989 and followed with biennial 
questionnaires. The present study included follow-up through 2013. This study 
included women who returned a supplementary 2008 questionnaire on trauma 
exposure and PTSD symptoms (N=54,763). This questionnaire was sent to a 
subsample of participants (N=60,804, response rate=90.1%). To retain participation 
in the ongoing longitudinal cohort, only women who have already returned their 
biennial questionnaire are sent supplementary questionnaires. Women missing data 
on trauma or PTSD symptoms (N=3,930) were excluded. This study was approved 
by the Institutional Review Board of Brigham and Women’s Hospital. Return of the 
questionnaire via US mail constitutes implied consent. 
Trauma exposure and PTSD symptoms were assessed on a supplementary 
2008 questionnaire. The 16-item Brief Trauma Questionnaire queried lifetime 
exposure to 15 types of traumatic events (e.g., serious car accident, sexual assault) 
and an additional item queried any traumatic event not covered in the other 
questions. 76 Respondents were asked to identify which trauma was their worst or 
most distressing; they were then asked their age at this worst trauma as well as their 
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age at their first trauma. PTSD symptoms were assessed in relation to their worst 
trauma with the 7-item Short Screening Scale for DSM-IV PTSD.77 Four or more 
symptoms on this scale have been associated with PTSD diagnosis (sensitivity=80%, 
specificity=97%, positive predictive value=71%, negative predictive value=98%).77 
For cases women with ≥4 PTSD symptoms were selected, for controls women with 
<4 PTSD symptoms (most had 0) were selected. 
 
Ohio National Guard (ONGA; Supplementary Data 1 #2)  
 See reference for details.111 A total of 37 potentially traumatic events were 
identified using the Clinician-Administered PTSD Scale (CAPS-IV)7 and the 1996 
Detroit Area Survey of Trauma.48 PTSD symptoms were assessed using a 17-item 
structured interview scale derived from the PTSD Checklist (PCL) for DSM-IV2 
performed by trained lay telephone interviewers using epidemiological methods 
(forced choice symptom severity range, 1-5). Reliability of the telephone interview 
was validated against the criterion standard (in-person CAPS interview by mental 
health professional) in a clinical subsample (N = 500), demonstrating high specificity 
(0.92).112 Respondents were considered to have a diagnosis if lifetime DSM-IV PTSD 
criteria were met. Respondents were considered to have a current diagnosis if past 
month DSM-IV criteria were met. The PCL calculates PTSD symptom severity, which 
ranged from 17 to 85, by sum of scores of items endorsed. For this cohort (125 
Cases, 125 Controls), the mean severity was 38.4 and the standard deviation 17.6. 
DNA for GWAS analysis was isolated from saliva (Oragene tube). The Institutional 
Review Board of VA Ann Arbor Health System approved this study. 
 
OPT (FEEN; Supplementary Data 1 #37) 
 Potentially traumatic events were identified using the standard trauma 
interview.30 The PSS-I was used to assess PTSD over the prior two weeks for the 
trauma of interest by postdoctoral and graduate level assessors trained to reliability.31 
The SCID-IV was used to assess lifetime PTSD (not current) for a single trauma not 
the focus of treatment.8 Respondents were considered to have a current PTSD 
diagnosis if they met DSM-IV diagnostic criteria and had a PSS-I score of 25 or 
greater. The PSS-I also provides PTSD symptom severity, with a range from 0 to 51. 
For this cohort (118 cases), the mean severity was 30.36 and the standard deviation 
6.91. DNA for GWAS analysis was isolated from blood. The Institutional Review 
Board of University Hospitals approved this study. 
 
Portugal (PORT; Supplementary Data 1 #20) 
 See reference for details.113 Potentially traumatic events were identified using 
CIDI, which included a module on DSM-IV PTSD that inquired about lifetime 
exposure to each of 27 different traumatic events (criterion A1). Respondents who 
reported ever experiencing any of the traumatic events were then asked about the 
number of exposures (NOE) and age at first exposure (AOE) for each.104 The CIDI 
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was used to assess PTSD over the prior Lifetime DSM-IV PTSD and other common 
DSM-IV disorders.104 DNA isolated from saliva. The Institutional Review Board of the 
Nova Medical School, Portugal, approved this study. 
 
PRISMO (PRIS; Supplementary Data 1 #25) 
 See reference for details.114 Potentially traumatic events were identified using 
a 19-item checklist.114 The Dutch Self-Rating Inventory for PTSD (SRIP) was used to 
assess PTSD one month prior to deployment and up to 2 years after deployment.115 
Respondents were considered to have a current diagnosis if a SRIP total score of ≥ 
38 at any measurement was met. The SRIP calculates PTSD symptom severity, 
which ranged from 22 to 88, by self-report. For this cohort (144 Cases, 815 Controls), 
the mean severity was 27.30 and the standard deviation 6.38. DNA for GWAS 
analysis was isolated from whole blood. The Institutional Review Board of Utrecht 
University Medical Center approved this study. 
 
Pregnancy Outcomes, Maternal and Infant Study Cohort (PROM; 
Supplementary Data 1 #23) 
 See reference for details.116 Potentially traumatic events were experiences of 
intimate partner violence [identified using Demographic Health Survey 
Questionnaires and Modules: Domestic Violence Module117 and the World Health 
Organization Multi-Country Study on Violence Against Women]118 and history of 
childhood abuse [identified using the Childhood Physical and Sexual Abuse 
Questionnaire adopted from the Center for Disease Control and Prevention Adverse 
Childhood Experiences Study].119 The Posttraumatic Stress Disorder Checklist – 
Civilian Version (PCL-C) was used to assess PTSD over the prior month.120 The 
PCL-C is a self-report measure with 17 items reflecting DSM-IV symptoms of PTSD 
and closely follows the Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV) criteria. For each item, participants were asked how bothered they were by a 
symptom over the past month on a 5-point Likert scale ranging from 1: “not at all” to 
5: “extremely” in regards to their most significant life event stressor. The total score 
on the PCL-C ranges from 17 to 85. Recent data from our team support that a PCL-C 
score of 26 or higher on the Spanish-language version, is associated with an 86% 
sensitivity and 63% specificity in diagnosing PTSD in a Peruvian population using the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria.120 
 All study procedures were approved by the Instituto Nacional Materno 
Perinatal in Lima, Peru, and the Office of Human Research Administration at the 
Harvard T.H. Chan School of Public Health, Boston, MA. 
 
Readiness and Resilience in National Guard Soldiers (RING; Supplementary 
Data 1 #33) 
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 See reference for details.121 Potentially traumatic events were identified using 
the Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) and items from the 
Deployment Risk and Resilience Inventory (DRRI)7,46 The CAPS-IV and the PTSD 
Checklist (PCL) were also used to assess PTSD currently (over the prior 2 weeks) 
and over the lifetime by trained interviewers and through self-report.7,122 The PCL 
calculates PTSD symptom severity, which ranged from 17 to 73 currently and 17 to 
85 lifetime, by self-report. For this cohort (41 Cases, 162 Controls), the mean current 
severity was 34.03 and the standard deviation was 13.48. The mean lifetime severity 
was 33.89 and the standard deviation was 12.98. Respondents were considered to 
have a lifetime diagnosis if they had a PCL score > 50 at the one-year post-
deployment time point. Respondents were considered to have a current diagnosis if 
the same criteria were met at the two-year post-deployment time point. The 
Institutional Review Board of the Minneapolis VA Health Care System approved this 
study. 
 
Risbrough/Norman randomized controlled psychotherapy trial (VRIS; 
Supplementary Data 1 #58) 
 See reference for details.123 Potentially traumatic events were identified using 
the life event checklist. The CAPS was used to assess PTSD over the prior over the 
past month by interviewers.68 Respondents were considered to have a diagnosis if 
DSM-5 diagnostic criteria using the CAPS-5 (a criterion A trauma and 2 or higher on 
1 re-experiencing symptom (criterion b), 1 avoidance symptom (criterion c), 2 
negative alterations in cognitions or mood (criterion d), and 2 hyperarousal symptoms 
(criterion e)) were met. The CAPS calculates PTSD symptom severity, which ranged 
from 0 to 80 by clinician rater of symptoms and severity. For this cohort (73 Cases, 5 
sub-clinical), the mean severity was 42 and the standard deviation 9.6. DNA for 
GWAS analysis was isolated from saliva using Oragene. The Institutional Review 
Board of The San Diego VA approved this study. 
 
Shared Roots (SHRS; Supplementary Data 1 #46) 
 See reference for details.66 Potentially traumatic events were identified using 
The Life Events Checklist for DSM-5 (LEC-5).66 The Clinician-Administered PTSD 
Scale for DSM-5 (CAPS-5)68 was administered by clinicians to assess PTSD over the 
prior month. The CAPS-5 and the PTSD Checklist for DSM-5 (PCL-5)59 calculates 
PTSD symptom severity, with a score range of 0 to 80, by adding scores ranging 
from 0 to 4 for all twenty items. For this cohort (164 Cases, 164 Controls), the mean 
severity on the PCL-5 was 33.0 and the standard deviation 23.9. A lifetime diagnosis 
of PTSD was not assessed for in this study. Respondents were considered to have a 
current diagnosis if DSM-5124 criteria based on the CAPS-5 were met. The 
Institutional Review Board of Stellenbosch University approved this study. 
 
Southeastern Europe PTSD (SEEP; Supplementary Data 1 #49) 
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 See reference for details.125 Potentially traumatic events were identified using 
Life Stressor List and List of traumatic events including frequency and severity of 
traumatic events.126 The CAPS was used to assess lifetime PTSD by medical 
personnel (psychiatrists, psychologists or psychiatric residents).7 Respondents were 
considered to have a diagnosis if DSM-IV criteria were met over lifetime. The CAPS 
calculates PTSD symptom severity, which ranged from 27 to 141. For this cohort 
(347 Cases, 339 Controls), the mean severity was 74.3 and the standard deviation 
20.2. DNA for GWAS analysis was isolated from EDTA blood. The Institutional 
Review Board of the universities of Sarajevo, Zagreb, Tuzla, Mostar, Prishtina and 
Würzburg approved this study. 
 
Study of Aftereffects of Trauma: Understanding Response in National Guard 
(SATU; Supplementary Data 1 #11)  
 See reference for details.127 Potentially traumatic events were identified using 
Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV).7 The CAPS-IV was also 
used to assess PTSD currently (over the prior 2 weeks) and over the lifetime by 
trained interviewers7. The CAPS-IV calculates PTSD symptom severity, which 
ranged from 0 to 105. For this cohort (88 Cases, 62 Controls), the mean severity was 
50.33 and the standard deviation 24.55. Respondents were considered to have a 
lifetime diagnosis if they met DSM-IV criteria for PTSD (measured using CAPS-IV) 
either current or past. Respondents were considered to have a current diagnosis if 
they met DSM-IV criteria for PTSD (measured using CAPS-IV) at the time of the 
assessment. The Institutional Review Board of the Minneapolis VA Health Care 
System approved this study. 
 
Sydney Neuroimaging (BRY2; Supplementary Data 1 #36) 
 Potentially traumatic events were identified using clinical interview to identify 
history of traumatic events. The CAPS was used to assess PTSD over the prior 4 
weeks by Masters level clinical interviewers.7 Respondents were considered to have 
a diagnosis if DSM-IV criteria were met. The CAPS calculates PTSD symptom 
severity, which ranged from 0 to 136, by clinical interview. For this cohort (82 Cases, 
86 Controls), the mean severity was 39.67 and the standard deviation 31.75. DNA for 
GWAS analysis was isolated from saliva. The Institutional Review Board of Western 
Sydney Area Health Service approved this study. 
 
VA Boston-National Center for PTSD Study (NCPT, TRAC; Supplementary Data 
1 #31, Supplementary Data 1 #32)  
 A total of 437 white non-Hispanic cases and 215 trauma-exposed controls is 
the composite of two datasets. The first from a cohort of white non-Hispanic subjects 
as described in a previous GWAS128 that passed ancestry filters as performed using 
SNPweights129 according to PGC-PTSD protocols (300 cases and 165 controls; 305 
males and 160 females). The majority of this sample consisted of US veterans, but 
21 
 
also included the intimate partners of a subset of the veterans. The second cohort 
was made up of subjects from the Translational Research Center for TBI and Stress 
Disorders, a VA RR&D Traumatic Brain Injury Center of Excellence at VA Boston 
Healthcare System (TRACTS) study of US veterans. From TRACTS, 137 white non-
Hispanic cases and 50 controls passed ancestry filters based on SNPweights and 
were included in the analysis. The TRACTS sample is largely male (170 men and 17 
women). The genotyping, quality control, filtering and imputation for these cohorts 
has been described in detail elsewhere.128,130 Briefly, genotyping was performed 
using the Illumina HumanOmni2.5-8 microarrays (Illumina, San Diego, CA). 
Imputation of non-genotyped SNPs was performed using IMPUTE2131-134 and 1000 
genomes phase 1 reference data.135 Principal components were generated by the 
program EIGENSTRAT136 based on 100,000 SNPs. For both cohorts, participants 
were administered the Clinician-administered PTSD scale for DSM-IV (CAPS-IV),7 a 
30-item structured diagnostic interview that assesses the frequency and severity of 
the 17 DSM-IV PTSD symptoms, 5 associated features and functional impairment, 
and both current and lifetime PTSD symptoms. These studies were performed under 
the oversight of the appropriate VA health care facilities institutional review boards. 
 
UK Biobank Cohort Description for PGC-PTSD (UKBB; Supplementary Data 1 
#60) 
 The UK Biobank is an epidemiological resource assessing a range of health-
related phenotypes in approximately 500,000 British individuals who were recruited 
between the ages of 40 and 70.137 Genome-wide genotype data is available on all 
participants, as well as a broad range of health phenotypes assessed at varying 
intensity. Data from an online follow-up questionnaire assessing common mental 
health traits, including questions designed to screen for PTSD, was available on 
157,366 individuals.138 
 Phenotype: PTSD phenotypes were derived from the mental health online 
follow-up of the UK Biobank (Resource 22 on http://biobank.ctsu.ox.ac.uk). 
Participants were asked six questions derived from the brief civilian version of the 
PTSD Checklist Screener (PCL-S;82) assessing PTSD symptoms in the prior month. 
Questions comprised three initial questions related to avoidance of activities, 
disturbing thoughts, and feeling upset, and three further questions related to feeling 
distant, feeling irritable and having trouble concentrating (UK Biobank fields 20494-
20498, 20508). Each item was scored on a five-point scale according to the amount 
of concern caused by that item in the past month (1="Not at all" to 5="Extremely"). 
The final item concerning trouble concentrating was drawn from an equivalent item 
from the Patient Health Questionnaire-9 (PHQ9) depression questionnaire and was 
scored on a four-point scale according to frequency of difficulties (1="Not at all" and 
4="Nearly every day"). All items were summed for each individual to yield a total 
score ranging 3-29. Cases were defined as all individuals with a PCL-S score ≥ 13, 
controls as all individuals who responded to all of the initial three questions and had 
PCL-S score ≤ 12. 
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 Two sensitivity analyses were performed to assess the stability of the UK 
Biobank PTSD phenotype. Firstly, controls were limited only to those who answered 
all initial questions with "Not at all" and so had a PCL-S score = 3. Secondly, PTSD 
cases and controls were limited to those reporting a lifetime trauma exposure. To 
assess the impact of reported trauma exposure on the PTSD phenotype, a trauma 
exposure measure was derived from questions in the mental health online follow-up 
that related to common triggers of post-traumatic stress-disorder.138 These questions 
asked if participants had ever: experienced combat; had a life-threatening accident; 
been diagnosed with a life-threatening illness; been a victim of a physically violent 
crime; been a victim of sexual assault; or witnessed a sudden violent death. 
Responses were combined to a single variable capturing any report of traumatic 
experience versus no report.  
 Genetic quality control: Genetic data for analyses was obtained from the full 
release of the UK Biobank data (N=487,410).139 Individuals were removed if this was 
recommended by the UK Biobank for unusual levels of missingness or 
heterozygosity; if call rate < 98% on genotyped SNPs; if they were related to another 
individual in the dataset (KING r < 0.044, equivalent to removing up to third-degree 
relatives inclusive); and if the phenotypic and genotypic gender information was 
discordant (X-chromosome homozygosity (FX) < 0.9 for phenotypic males, FX > 0.5 
for phenotypic females). Removal of relatives was performed using a greedy 
algorithm, which minimise exclusions (for example, by excluding the child in a 
mother-father-child trio). All analyses were limited to individuals of White Western 
European ancestry, as defined by 4-means clustering on the first two genetic 
principal components provided by the UK Biobank.140 Principal components analysis 
was also performed on the European-only subset of the data using the software 
package flashpca2141. After quality control, individuals were excluded from analysis if 
they did not complete the mental health online questionnaire (N=126,522). 
 Genetic analyses used imputed variants provided by the UK Biobank.139 
Autosomal genotype data from two highly-overlapping custom genotyping arrays 
(covering ~800,000 markers) underwent centralised quality control to remove 
genotyping errors before being imputed in a two-stage imputation to the Haplotype 
Reference Consortium (HRC) and UK10K (for rarer variants not present in the HRC) 
reference panels (142;143;139). In addition, this central quality control, variants for 
analysis were limited to common variants (minor allele frequency > 0.01) imputed 
with higher confidence (IMPUTE INFO metric > 0.4). In addition, only variants that 
were directly genotyped or that were imputed from the HRC were included.142 
 Genome-wide association analyses: Prior to analysis, PTSD status was 
residualised on six prinicipal components from the genetic data and factors capturing 
genotyping batch and recruitment centre, using logistic regression. GWAS were then 
performed on the resulting deviance residuals using linear regressions on imputed 
genotype dosages in BGenie v1.2, software written for genetic analyses of UK 
Biobank.139 
 
Vietnam Era Twin Study of Aging (VETS; Supplementary Data 1 #24) 
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 See references for details.144,145 Potentially traumatic events were identified 
using the Combat Exposure Index146 and the Diagnostic Interview Schedule Version 
III-Revised (DIS-III-R).DIS-III-R; 147 The Vietnam Era Twin Registry PTSD scale148 
(administered at average age 38) was used to assess PTSD symptoms over the past 
6 months and the PCL-civilian version for DSM-IV149 (administered at average age 
62) was used to assess PTSD over the prior month. These two instruments correlate 
0.90 when administered at the same time.150 The 17-item PCL calculated PTSD 
symptom severity, which ranged from 17 to 84. Each response was rated on a 1-5 
scale (from “not at all” to “extremely”). For this cohort (60 Cases, 841 Controls), the 
mean severity was 26.2 and the standard deviation was10.5. For this analysis, 
respondents were considered to have a diagnosis of PTSD if they met DSM-III-R 
criteria based on the DIS-II-R interview. DNA for GWAS analysis was isolated from 
blood. Genotyping was performed by deCODE Genetics, Reykjavik, Iceland. The 
Institutional Review Boards of the University of California, Sand Diego, Boston 
University, and the Puget Sound VA Healthcare System approved this study. 
 
The Women and Children’s Health Study (WACH; Supplementary Data 1 #43) 
 See reference for details.151 Potentially traumatic events were identified using 
the Life Events Checklist (LEC) for DSM-5.66 The PTSD Checklist for DSM-5 (PCL-5) 
was used to assess PTSD over the lifetime by interviewers.152 Respondents were 
considered to have a diagnosis of PTSD if the PCL-5 score was >=38. Respondents 
were considered to have a current diagnosis based only upon self-report during the 
interview. The PCL-5 calculates PTSD symptom severity, which ranged from 0 to 79. 
For this cohort (151 Cases, 150 Controls), the mean severity was 52.4 (SD: 11.2) for 
cases and 31.0 (SD: 23.5) for controls DNA for GWAS analysis was isolated from 
blood. The Institutional Review Board of the Louisiana State University Health 
Sciences Center-New Orleans approved this study. 
 
Yale-Penn Study (GSDC; Supplementary Data 1 #6)  
 See reference for details.153 Sample collection and diagnostic interviews were 
performed by trained interviewers using the Semi-Structured Assessment for Drug 
Dependence and Alcoholism (SSADDA; available at 
https://zork.wustl.edu/nida/study_descriptions/study_1/ssaddav11_2_ns.pdf) to 
derive diagnoses for lifetime psychiatric and substance use disorders based on DSM-
IV criteria. Twelve types of traumatic events were assessed: experienced direct 
combat in a war; seriously physically attacked or assaulted; physically abused as a 
child; seriously neglected as a child; raped; sexually molested or assaulted; 
threatened with a weapon; held captive or kidnapped; witnessed someone being 
badly injured or killed; involved in a flood, fire, or other natural disaster; involved in a 
life-threatening accident; suffered a great shock because one of the above events 
happened to someone close to you; and other. Participants were asked to list up to 
three traumatic events and describe the trauma in detail. Those reporting traumatic 
experiences were then interviewed for potential PTSD symptoms. After the data were 
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scored, PTSD diagnoses were generated based on DSM-IV criteria. The institutional 
review boards at Yale University School of Medicine, the University of Connecticut 
Health Center, the University of Pennsylvania School of Medicine, the Medical 




Supplementary Note 1 
 
Participating studies and ancestry compositions 
 The PGC-PTSD Freeze 2 dataset (PGC2) is comprised of a total of 206,655 
subjects (32,428 PTSD cases and 174,227 controls) with available genotype and 
phenotype information (Supplementary Data 1). PGC2 includes subjects from 9 
studies already reported in Freeze 1154, 50 (combined into 47) new studies (together 
forming Freeze 1.5: N = 80,467 subjects, 22,039 cases, 58,428 controls), and the 
large European ancestry UK Biobank study (UKBB; N = 126,188 subjects, 10,389 
cases, 115,799 controls). Mean study age of these subjects ranged from 13.35 – 
69.1 years (mean 52.4 years), and the male/female ratio ranged from all female (N = 
7) to all male (N = 3) studies (mean 49.7% male). 
 PGC1.5 included populations from South Africa, Europe, and the Americas, 
and only 56.5% of subjects with individual-level genotype data were of European 
ancestry (Supplementary Table 12). After classification of subjects into main 
ancestral groups (Supplementary Figure 1) and removal of related subjects, a total of 
195,701 subjects (94.7%; 29,556 PTSD cases and 166,145 controls) remained to be 
included in the European (EUA), African (AFA), and American ancestry (AMA) meta-
analyses (Supplementary Tables 3, 5, 6). Due to the smaller sample size (N = 5,703 
subjects), the AMA meta-analysis was only considered in trans-ancestry analyses 
and replication of the top hits in the EUA and AFA GWAS. 
 
Polygenic effects vs. population stratification 
 Meta-analyses were performed for the EUA, AFA, and AMA GWAS in both 
sexes and separately in men and women. Quantile-quantile plots across all analyses 
showed low genome-wide inflation of the test statistics (Supplementary Figure 2). To 
further distinguish true polygenic effects from potential population stratification and 
cryptic relatedness (e.g. among subjects from studies sharing summary data) within 
these inflation statistics, the LDSC intercept method was used (EUA analyses only). 
In the meta-analysis including both sexes, the estimated polygenic effects account 
for 72% (SE = 0.082) of the observed inflation (Supplementary Figure 2, panel A), 
with a remaining modest but significant inflation (intercept = 1.022, SE = 0.006, P = 
6.22 x 10-4) potentially reflecting cryptic relatedness, population stratification, and/or 
sample size. In the male-only analysis (Supplementary Figure 2, panel E), the 
polygenic effects account for 15% of the test statistics, with a remaining modest but 
significant inflation (intercept =1.026, SE = 0.006, P =  9 x 10-6), and in the female-
only analysis polygenic effects account for 100% of the observed genome-wide 
inflation of the test statistics (Supplementary Figure 2, panel I), with no significant 
evidence of remaining inflation (intercept = 0.989, SE = 0.006, P = 0.08). 
 
Sensitivity analyses for heritability estimates in UK Biobank using alternative 
subject selection criteria 
Because the UKBB contributed a substantial number of subjects to PGC2 (45% of 
the EUA cases), we performed additional heritability analyses using two additional, 
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more restrictive case and control definitions (Supplementary Table 1, p2 and p3). 
Heritability point estimates in these smaller data sets remained similar across all 
analyses; as expected, h2snp was most significant in the largest, least restrictive 
subject pool (p1). Importantly, in the UK biobank, h2snp estimates were not different 
between men and women across all subject selection criteria (P >0.4 in all cases). 
Subsequent GWAS analyses were based on the UKBB phenotype including the 
largest number of subjects (P1; N = 126,188). 
 
Local ancestry inference (LAI) 
To deconvolute local ancestry across the genome of admixed subjects we developed 
a custom LAI pipeline (see Methods and Supplementary Figure 23 for details). 
Overall, we found that global ancestry proportions for admixed individuals calculated 
from local ancestry tracts were highly concordant with ancestry estimates generated 
by PCA-based SNPweights (see Methods; correlations: r = 0.950 for the European 
ancestry components, and r = 0.992 for African ancestry, N = 7,206 mixed-ancestry 
subjects from the entire GTPC). 
 Local ancestry analyses for the two lead SNPs from the genome-wide 
significant genomic regions in AFA are presented in the Supplementary Tables 7-8. 
Only subjects with available genotype data are included in these analyses. An 
analysis of allele frequencies stratified by copies and type of ancestral haplotypes 
showed that rs115539978 is present predominantly on the African background (MAF 
8-9%), with MAF< 1% on the European and Native American background 
(Supplementary Table 7). Inclusion of LAI covariates did not influence the effect of 
rs115539978 on PTSD (i.e., global PC’s appropriately controlled for admixture; panel 
B). Due to differences in allele frequencies, rs115539978 is an ancestry-specific 
PTSD risk variant. The male-specific hit with lead SNP rs142174523 was common on 
all ancestral backgrounds (Supplementar Table 8). Association with PTSD was 
robust to inclusion of LAI covariates, and the minor allele had a similar, protective 
effect on the African and European background (OR = 0.8). 
 
Biological function of genes and psychiatric relevance 
Functional annotation of the 6 GWAS hits and gene-based analyses using FUMA 
predicted 12 genes to be associated with PTSD in the EUA and AFA GWAS (Table 
4). 
 ZDHHC14 (Zinc finger, DHHC-type containing 14): ZDHHC14 encodes a 
palmitoyltransferase that is expressed in the brain155 and evidence from other DHHC 
containing palmitoyl acyltransferases support a role for dysregulated palmitoylation 
contributing to neuropsychiatric disorders156. ZDHHC14 was previously identified as 
a candidate gene for bipolar disorder by linkage and convergent functional genomics 
studies157, but to date GWAS does not support a significant association between 
ZDHHC14 and bipolar disorder. 
 PARK2 (Autosomal recessive juvenile Parkinson disease-2) is a component of 
the E3 ubiquitin ligase complex and is known to have several functions158, including 
the autophagy of dysfunctional mitochondria, which plays a neuroprotective role in 
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familial Parkinson’s disease.159 PARK2 may also act to regulate innate immunity and 
inflammation65,160,161 and function as a tumor suppressor 162. PARK2 shows an 
extensive alternative splicing pattern163, however, the role of different isoforms in the 
brain is not well understood. PARK2 codes for PARKIN, loss of function of the 
PARKIN protein leads to dopaminergic cell death although the mechanism by which 
this occurs is not clear. The dopaminergic system has an important role in fear 
conditioning, which is critical in the development and maintenance of PTSD.164 
Abnormal expression of PARK2 has been seen in major depressive disorder and 
schizophrenia cases.165  
 KAZN (Kazrin, periplakin interacting protein) codes for a highly conserved 
protein that is noted for being important in the formation of the cornified envelope of 
keratinocytes but expression throughout the body suggests it has other important 
developmental functions.166 KAZN is moderately expressed in the brain 155,167, where 
it has been found to be underexpressed in parvalbumin neurons of the superior 
temporal cortex of schizophrenia cases.168 Notably, dysfunction of PV interneurons is 
casually linked to many mental disorders including PTSD.169 KAZN is overexpressed 
in the substantia nigra of Parkinson's cases.170  
 TMEM51-AS1 (transmembrane protein 51 antisense) is the non-coding 
antisense transcript to TMEM51. No additional information regarding their role in the 
human or rodent brain is available. 
 The C2H2 zinc-finger binding motif of ZNF813 (zinc finger protein 813) and 
the predicted nuclear location of its product suggest a role in DNA binding and 
transcriptional activity, however, its function in vitro and in-vivo remains unclear. It is 
weakly expressed in the human brain.155 
 Gene-based analyses in EUA further identified 2 genes. 
 SH3RF3 (SH3 Domain Containing Ring Finger 3): encodes a protein that contains 
four Src homology 3 domains as well as a RING finger domain that confers E3 
ubiquitin ligase activity171. Src homology 3 domains mediate protein-protein 
interactions172 and E3 ubiquitin ligase genes are important in development of 
neurological diseases.173,174 SH3RF3 is ubiquitously expressed, with moderate 
expression seen in the frontal cortex.155,167 A linkage study of Alzheimer's disease 
found an association between SH3RF3 and disease age of onset 175.  
 PODXL (Podocalyxin-like protein 1) encodes a protein involved in regulation of 
cellular adhesion and morphology, that is particularly noted for being important in 
kidney development and abnormally expressed in a variety of cancers.176 In the 
brain, PODXL is expressed in microvessels and may be important in the formation or 
function of the blood brain barrier.177 Genomics studies have implicated PODXL in 
several disorders including alcoholism178, Alzheimer's disease 179, bipoar disorder180, 
epilepsy181, and schizophrenia.182 
 For our top AFA association, FUMA mapped the SNP to LINC02335, 
MIR5007, and TUC338. There is little information available about the functional role 
of any of these RNAs. MIR5007 was marginally associated with eye movement 
phenotypes in related to psychotic disorders (P = 3 x 10-7).183 
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 The top SNP in AFA males was mapped to LINC02571 and HLA-B (Major 
Histocompatibility Complex, Class I, B) in the human leukocyte antigen region. This 
region plays a major role in immune function and has repeatedly been associated 
with psychiatric illnesses.184,185 Lead SNP rs142174523 is a putative pleiotropic SNP 
for rheumatoid arthritis and schizophrenia.186 It is ~700KB away from the most 
significant schizophrenia hit187, but localization of functional variants in this region is 
notably difficult and can require extensive follow up. 
 
Functional annotation of variants in risk loci 
FUMA188 was also used for functional annotation of variants in the 6 genome-wide 
significant regions (see id's 30-33 at [https://fuma.ctglab.nl/browse]). For the first EUA 
locus (Supplementary Figure 24, Table 4), one SNP (rs35262389) in LD with the lead 
SNP rs34517852 has a Combined Annotation-Dependent Depletion (CADD) score of 
15.28 that may be indicative of this being the functional variant of this locus. Another 
SNP (rs9348095) in LD has a CADD score of 9.498 and RegulomeDB indicates that 
this variant is located in the TSS of ZDHHC14, potentially influencing its 
transcriptional activity. Hi-C data further indicated that the risk locus, which is 
upstream of ZDHHC14, interacts with elements further downstream in ZDHHC14, 
potentially regulating transcriptional activity. 
 For the second EUA locus (lead SNP rs9364611), chromatin state analysis 
showed that most of the locus is transcriptionally quiescent, however, a few SNPs 
are located in enhancer sites or weakly transcribed regions when tested in across 
neuronal cell lines/tissues. Hi-C data show further that the risk locus forms physical 
contact with another site in the same intron of PARK2; however, the functional 
implications of this interaction remain unknown. 
 No variants had significant or relevant functional evidence in the top locus 
identified in the EUA males (lead SNP rs571848662). 
 For the second locus (lead SNP rs148757321), chromatin state analyses 
showed only a weak transcription signal across all neuronal cell lines/tissues. Hi-C 
chromatin interaction data show significant interactions with regions upstream of 
KAZN without further evidence for a functional role of this interaction. 
The AFA locus with lead SNP rs115539978 contained a few SNPs associated 
with heterochromatin and enhancer function. Hi-C chromatin interaction data showed 
significant chromatin conformation interactions between the risk region and a region 
approximately 1,100kb upstream harboring additional non-coding RNAs including 
LINC00458, hsa-mir-1297 and LINC00558 as well as a region approximately 820kb 
downstream harboring the pseudogene HNF4GP1.  
For the locus in AFA males with lead SNP rs142174523, RegulomeDB scores 
indicate potential regulatory functions of SNPs in the locus on transcription factor 
binding and eQTL function. This is in line with the chromatin state analyses that show 
some heterochromatin enrichment across all neuronal cell lines/tissues as well as 
stretches of PolyComb repressed chromatin. Furthermore, eQTL analyses did show 
significant associations with gene expression in ATP6V1G2, C4A, C4B, CCHCR1, 
CYP21A1P, DDR1, HCG27, HLA-B, HLA-C, MICB, NOTCH4, POU5F1, PSORS1C3, 
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SKIV2L, VARS, and VARS2 across the different eQTL databases used. 
 
Regulation of non-coding RNAs by the African ancestry specific GWAS hit 
rs115539978 
To gain deeper insight into the function of rs115539978 on expression of non-coding 
RNAs at this locus we used 12 lymphoblastoid cell lines (LCLs) from the AFR 
superpopulation of the 1000 Genomes Project (Supplementary Table 13). 
Prior evidence suggests that hsa-mir-5007 may not be an expressed miRNA167,189 
and RNA-seq data from our lab in peripheral blood and post-mortem brain tissue did 
not reveal expression of this particular miRNA (data not shown). However, using a 
qPCR approach we detected expression of Linc00458 and TUC338 (Supplementary 
Table 14).190 Linc02335 was weakly expressed and Linc00558 was not expressed in 
the LCLs used. 
 We next tested if rs115539978 genotype influences differential expression of 
Linc00458, TUC338 and Linc02335 under basal conditions, however, we did not 
observe expression differences for any of the RNAs tested (Linc00458: F(1,9) = 
1.452, P =  0.259; TUC338: F(1,9) = 2.828, P =  0.127; Linc02335: F(1,9) = 0.036, P 
=  0.854). 
 We next tested the hypothesis that genotype dependent differences in RNA 
expression may emerge only after in-vitro activation of the glucocorticoid receptor, 
using dexamethasone representing a pharmacological stress-exposure condition. Of 
note, Linc02335 has been previously described as a Dex responsive gene in airway 
smooth muscle cells.191 Indeed, genotype dependent differences in RNA expression 
emerged after 4 hours Dex stimulation for Linc00458 and TUC338 with a 
downregulation of these RNAs in cells carrying the major allele compared to the 
minor (risk) allele (Linc00458: F(1,9) = 5.328, P =  0.046; TUC338: F(1,9) = 5.425, P 
=  0.045) (Supplementary Figure 25 B and D). Similar differences were observed for 
TUC338 in ethanol vehicle control experiments but not for Linc00458 (UC338: F(1,9) 
= 7.940, P =  0.02; Linc00458: F(1,9) = 1.571, P =  0.242) (Supplementary Figure 25 
A and C). Thus, rs115539978 may influence the expression of non-coding RNAs in 
response to increased glucocorticoid receptor signaling, thus linking this African-
specific genetic variant to stress response and non-coding RNA expression. The 
biological roles of both TUC338 and Linc00458 in the brain remain unknown. 
Linc00458 (BC026300) was previously described as an exclusive transcript in human 
embryonic stem cells, and implicated in the regulation of pluripotency via direct 
interaction with SOX2.190 The human genome contains several copies of TUC338. 
Although a TUC338 transcript from chromosome 12 has been assigned a functional 
role in hepatocellular carcinoma cell growth192, it remains unclear if other TUC338 
copies share similar functions. To date, no brain-specific role for TUC338 has been 
described. 
 
Deep phenotyping exploration of the African ancestry top hit rs115539978 
To explore the African-specific lead variant in more detail we tested the hypothesis 
that rs115539978 is associated with intermediate phenotypes previously associated 
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with PTSD, including functional imaging phenotypes and psychophysiology. PGC-
PTSD includes a large number of extensively phenotyped studies, and working 
groups across multiple biological systems are focused on implementing pipelines for 
functional follow-up of genomic regions of interest.193 Data were used from a 
subsample of the Grady Trauma Project (study #47, GTPC), where individual genetic 
data and detailed phenotypic data were readily available. GTPC is the largest PGC2 
AFA dataset (Supplementary Table 5) and shows significant association of 
rs115539978 with PTSD diagnosis (P < 4.55 x 10-7, Supplementary Figure 14). 
 Neuroimaging: Examining brain structure (size) using freesurfer, we examined 
amygdala bilateral average volume in rs115539978 CC genotype vs. T carriers. We 
found greater amygdala volume in the rs115539978 T-carriers (1689uL, N = 14), 
relative to subjects homozygous for the C-allele (1549uL, N = 73), F(1,87) = 5.0, P =  
0.03 (Supplementary Figure 26 A). Although there is evidence for an overall 
reduction of amygdala volume in PTSD in some previous literature, the most robust 
effects are generally for hippocampal volume (194).  Furthermore, larger amygdala 
volumes and enhanced functional connectivity were reported with increases in fear- 
and anxiety related symptoms 195. Finally, there is a long history of increase dendritic 
arborization and amygdala volume in animal models of chronic stress.196 
 Psychobiology: We examined the role of rs115539978 in association with fear 
potentiated startle habituation – a physiological phenotype known to be, in part, 
amygdala dependent.197 We found a significant effect of rs115539978 genotype on 
habituation to startle CS+ (from block 2 to block 3 (ACQ_HAB)), a variable that 
captures habituation to the conditioned aversive stimulus. The main effect of SNP is 
significant at P = 0.048 (N=248 CC and 51 T carriers) comparing the CC to CT 
genotype (TT-carriers are not available). The significance is maintained (P = 0.044) if 
we covary for demographic variables (age and sex) (Supplementary Figure 26 B). 
Thus, this lead SNP seems to capture a genomic region that regulates ncRNA 
expression related to stress response and is also associated with increased 
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Supplementary Figure 1: Standardized global ancestry grouping for PGC-PTSD Freeze 






Supplementary Figure 2: Quantile-quantile plots of expected versus observed -log10 p-







Supplementary Figure 3: Manhattan plots from meta-analyses of GWAS in women 
showing no genome-wide significant loci in subjects of A) European and B) African 





Supplementary Figure 4: Regional association plots (Locus zoom) of the European 
ancestry top hit rs34517852 in the EUA meta-analysis. Chromosomal position is indicated 
on the x-axis, -log10 P-values for each SNP (filled circles) is indicated on the y-axis, with the 
lead SNP shown in purple. Annotated genes in the region are drawn in the lower panel. 
Recombination rate is indicated by a blue line. Additional SNPs in the locus are colored 





Supplementary Figure 5: Regional plots (Locus zoom) of the European ancestry 
second hit rs9364611 in the EUA meta-analysis. Chromosomal position is indicated on the 
x-axis, -log10 P-values for each SNP (filled circles) is indicated on the y-axis, with the lead 
SNP shown in purple. Annotated genes in the region are drawn in the lower panel. 
Recombination rate is indicated by a blue line. Additional SNPs in the locus are colored 





Supplementary Figure 6: Regional plots (Locus zoom) of the European ancestry male 
top hit rs571848662 (gray circle) in the EUA sex-stratified meta-analysis. Chromosomal 
position is indicated on the x-axis, -log10 P-values for each SNP (filled circles) is indicated on 
the y-axis, with the lead SNP shown in purple. Annotated genes in the region are drawn in 
the lower panel. Recombination rate is indicated by a blue line. Additional SNPs in the locus 
are colored according to linkage disequilibrium (r2) with the lead SNP. The second most 
significant hit in the region, rs8112292, is marked as target variant (purple circle) for r2 






Supplementary Figure 7: Regional plots (Locus zoom) of the European ancestry male 
second hit rs148757321 (gray circle) in the EUA sex-stratified meta-analysis. 
Chromosomal position is indicated on the x-axis, -log10 P-values for each SNP (filled circles) 
is indicated on the y-axis, with the lead SNP shown in purple. Annotated genes in the region 
are drawn in the lower panel. Recombination rate is indicated by a blue line. Additional SNPs 
in the locus are colored according to linkage disequilibrium (r2) with the lead SNP. The 
second most significant hit in the region, rs514370, is marked as target variant (purple 
diamond) for r2 estimates in LocusZoom because the because the reference panel for LD 





Supplementary Figure 8: Regional plots (Locus zoom) of the African ancestry top hit 
rs115539978 (purple diamond) in the AFA meta-analysis. Chromosomal position is 
indicated on the x-axis, -log10 P-values for each SNP (filled circles) is indicated on the y-
axis, with the lead SNP shown in purple. Annotated genes in the region are drawn in the 
lower panel. Recombination rate is indicated by a blue line. Additional SNPs in the locus are 





Supplementary Figure 9: Regional plots (Locus zoom) of the African ancestry male top 
hit rs142174523 (purple diamond) in the AFA sex-stratified meta-analysis. 
Chromosomal position is indicated on the x-axis, -log10 P-values for each SNP (filled circles) 
is indicated on the y-axis, with the lead SNP shown in purple. Annotated genes in the region 
are drawn in the lower panel. Recombination rate is indicated by a blue line. Additional SNPs 





Supplementary Figure 10: Forest plot (left panel) of the European top hit rs34517852 
(P =  3.16 x 10-9) showing effect sizes for each of the 40 included GWAS in the EUA 
meta-analysis. The PM-Plot (right panel) is separating studies predicted to have an effect on 
PTSD (red) from underpowered studies with ambiguous effects (green) or predicted to have 
no effect (blue). For a detailed study description see Supplementary Methods and 





Supplementary Figure 11: Forest plot (left panel) of the European second hit 
rs9364611 (P =  4.36 x 10-8) showing effect sizes for each of the 43 included GWAS in 
the EUA meta-analysis. The PM-Plot (right panel) is separating studies predicted to have 
an effect on PTSD (red) from underpowered studies with ambiguous effects (green) or 
predicted to have no effect (blue). For a detailed study description see Supplementary 





Supplementary Figure 12: Forest plot (left panel) of the male European ancestry top 
hit rs571848662 (P =  7.88 x 10-9) showing effect sizes for each of the 31 included 
GWAS in the male EA meta-analysis. The PM-Plot (right panel) is separating studies 
predicted to have an effect on PTSD (red) from underpowered studies with ambiguous 
effects (green) or predicted to have no effect (blue). For a detailed study description see 





Supplementary Figure 13: Forest plot (left panel) of the male European ancestry 
second hit rs148757321 (P =  3.76 x 10-8) showing effect sizes for each of the 31 
included GWAS in the male EUA meta-analysis. The PM-Plot (right panel) is separating 
studies predicted to have an effect on PTSD (red) from underpowered studies with 
ambiguous effects (green) or predicted to have no effect (blue). For a detailed study 





Supplementary Figure 14: Forest plot (left panel) of the African ancestry  top hit 
rs115539978 (P =  2.79 x 10-8) showing effect sizes for each of the 21 included GWAS in 
the AFA meta-analysis. The PM-Plot (right panel) is separating studies predicted to have an 
effect on PTSD (red) from underpowered studies with ambiguous effects (green) or predicted 
to have no effect (blue). For a detailed study description see Supplementary Methods and 





Supplementary Figure 15: Forest plot (left panel) of the male African ancestry  top hit 
rs142174523 (P =  4.31 x 10-8) showing effect sizes for each of the 13 included GWAS in 
the male AFA meta-analysis. The PM-Plot (right panel) is separating studies predicted to 
have an effect on PTSD (red) from underpowered studies with ambiguous effects (green) or 
predicted to have no effect (blue). For a detailed study description see Supplementary 





Supplementary Figure 16: Comparison of the European ancestry top hit rs34517852 
across the European (EUA), African (AFA), and Latino (AMA) PTSD GWAS. 
Chromosomal position of the regional association plots is indicated on the x-axis, -log10 P-
values for each SNP (filled circles) is indicated on the y-axis, with the lead SNP shown in 
purple. Annotated genes in the region are drawn in the lower panel. Recombination rate is 
indicated by a blue line. Additional SNPs in the locus are colored according to linkage 
disequilibrium (r2) with the lead SNP. A1 allele 1 (coded allele), A2 allele 2, A1 Freq A1 allele 





Supplementary Figure 17: Comparison of the European ancestry second hit rs9364611 
across the European (EUA), African (AFA), and Latino (AMA) PTSD studies. 
Chromosomal position of the regional association plots is indicated on the x-axis, -log10 P-
values for each SNP (filled circles) is indicated on the y-axis, with the lead SNP shown in 
purple. Annotated genes in the region are drawn in the lower panel. Recombination rate is 
indicated by a blue line. Additional SNPs in the locus are colored according to linkage 
disequilibrium (r2) with the lead SNP. A1 allele 1 (coded allele), A2 allele 2, A1 Freq A1 allele 





Supplementary Figure 18: Comparison of the European ancestry male top hit 
rs571848662 across the European (EUA), African (AFA), and Latino (AMA) PTSD 
studies. Chromosomal position of the regional association plots is indicated on the x-axis, -
log10 P-values for each SNP (filled circles) is indicated on the y-axis, with the lead SNP 
shown in purple. Annotated genes in the region are drawn in the lower panel. Recombination 
rate is indicated by a blue line. Additional SNPs in the locus are colored according to linkage 
disequilibrium (r2) with the lead SNP. A1 allele 1 (coded allele), A2 allele 2, A1 Freq A1 allele 





Supplementary Figure 19: Comparison of the European ancestry male second hit 
rs148757321 across the European (EUA), African (AFA), and Latino (AMA) PTSD 
studies. Chromosomal position of the regional association plots is indicated on the x-axis, -
log10 P-values for each SNP (filled circles) is indicated on the y-axis, with the lead SNP 
shown in purple. Annotated genes in the region are drawn in the lower panel. Recombination 
rate is indicated by a blue line. Additional SNPs in the locus are colored according to linkage 
disequilibrium (r2) with the lead SNP. A1 allele 1 (coded allele), A2 allele 2, A1 Freq A1 allele 





Supplementary Figure 20. Comparison of the African ancestry top hit rs115539978 
across the African (AFA), European (EUA), and Latino (AMA) PTSD studies. 
Chromosomal position of the regional association plots is indicated on the x-axis, -log10 P-
values for each SNP (filled circles) is indicated on the y-axis, with the lead SNP shown in 
purple. Annotated genes in the region are drawn in the lower panel. Recombination rate is 
indicated by a blue line. Additional SNPs in the locus are colored according to linkage 
disequilibrium (r2) with the lead SNP. A1 allele 1 (coded allele), A2 allele 2, A1 Freq A1 allele 





Supplementary Figure 21. Comparison of the African ancestry male top hit 
rs142174523 across the African (AFA), European (EUA), and Latino (AMA) PTSD 
studies. Chromosomal position of the regional association plots is indicated on the x-axis, -
log10 P-values for each SNP (filled circles) is indicated on the y-axis, with the lead SNP 
shown in purple. Annotated genes in the region are drawn in the lower panel. Recombination 
rate is indicated by a blue line. Additional SNPs in the locus are colored according to linkage 
disequilibrium (r2) with the lead SNP. A1 allele 1 (coded allele), A2 allele 2, A1 Freq A1 allele 





Supplementary Figure 22. Manhattan plots from trans-ancestry meta-analyses of 
GWAS for PTSD including subjects of European, African, and Latino ancestries. 
Results are shown for GWAS in all subject subjects (panel A), and for sex-stratified analyses 
in men (panel B) and women (panel C), respectively. The red line represents genome-wide 






Supplementary Figure 23. Example of a painted karyogram showing ancestral 
population tracts across the autosomes of an African American individuals. EUR 





Supplementary Figure 24. Hi-C data providing evidence for chromatin interaction of 
the African-ancestry GWAS meta-analysis top hit rs115539978. SNP rs115539978 is on 
chromosome 13 with a region about 1,100kb upstream harboring additional non-coding 
RNAs including LINC00458, hsa-mir-1297 and LINC00558 as well as a region approximately 
820kb downstream harboring the pseudogene HNF4GP1. Chromosomal position of the 
regional association plots is indicated on the x-axis, -log10 P-values for each SNP (filled 
circles) is indicated on the y-axis, with the lead SNP shown in purple. Additional SNPs in the 






Supplementary Figure 25. Dexamethasone-induced differential expression of 
Linc00458 and UC338 is rs115539978 genotype dependent. Vehicle control experiments 
for Linc00458 (panel A) and TUC338 (panel C), and Dex stimulation for Linc00458 (panel B) 





Supplementary Figure 26. Neuroimaging and physiology related to the African 
ancestry top hit rs115539978. Neuroimaging findings (panel A) and physiological findings 
(panel B) comparing carriers of the minor T-allele versus homozygous subjects for the C-
allele in African-American subjects from the Grady Trauma project (study #47, GTPC) 
showing significant differences in left amygdala volume (N = 73 CC, and 14 T-allele carriers, 
P = 0.03) and with fear potentiated startle habituation (N = 248 CC, and 51 T carriers, P = 
0.048). SNP effects were identified after controlling for ancestry components PCs 1-5, age, 
and intracranial volume (ICV). There was no effect of SNP on ICV, P = 0.76. Box and 
whisker plots show median and interquartile range in each group. Brain image shows a 3D 
rendering of the left amygdala segmentation for a representative participant, overlaid on a 







Supplementary Figure 27. Polygenic risk score (PRS) plot from PRSice showing 
results at broad P-value thresholds for PGC2 PTSD GWAS predicting PTSD re-
experiencing symptoms in Million Veteran Program (MVP).198 A bar for the best-fit PRS 
(P =  5.2 x 10-62) from the high-resolution run at a p-value threshold of 0.3 is also included 






Supplementary Figure 28: Schematic of the local ancestry pipeline developed to infer 













PTSD screening in UKBB was based on self-reported symptoms from a mental health survey. 
Estimates are calculated at different population prevalences after trauma exposure, for alternative subject selection criteria, and 
separately for men and women.  
P-value is testing if h2SNP is different from zero and applies to all prevalences, UKBB UK Biobank European subjects, UKBB_p1 all 
cases and controls (cases: PCL>=13; controls: PCL<13), UKBB_p2 only trauma-exposed cases and controls (cases: PCL>=13; 
controls: PCL<13) UKBB_p3 only trauma-exposed cases and controls (cases: PCL>=13; controls: PCL=4), h2snp mean SNP-based 
heritability, SE standard error, CI confidence interval; z test-statistic 
  
10% prevalence 30% prevalence 50% prevalence
Group Sample N  SNPs N  Cases N Controls N Total h 2 SNP SE 95% CI h
2
SNP SE 95% CI h
2
SNP SE 95% CI z p ‐value
All UKBB_p1 1,175,791 10,389      115,799      126,188 0.13 0.01 0.1 ‐ 0.15 0.17 0.02 (0.1 ‐ 0.15) 0.19 0.02 0.15 ‐ 0.23 8.75 2.1 x 10‐18
UKBB_p2 1,280,135 7,047         56,988        64,035 0.13 0.02 0.08 ‐ 0.17 0.17 0.03 (0.08 ‐ 0.17) 0.19 0.03 0.12 ‐ 0.25 5.76 8.5 x 10‐9
UKBB_p3 1,280,135 7,047         26,935        33,982 0.19 0.02 0.14 ‐ 0.23 0.26 0.03 (0.14 ‐ 0.23) 0.28 0.04 0.21 ‐ 0.35 7.79 6.4 x 10‐15
Men UKBB_p1 1,175,791 3,544         51,700        55,244 0.11 0.04 0.04 ‐ 0.17 0.15 0.05 (0.04 ‐ 0.17) 0.16 0.05 0.05 ‐ 0.26 2.99 1.4 x 10‐3
UKBB_p2 1,280,135 2,658         28,443        31,101 0.10 0.06 ‐0.02 ‐ 0.22 0.14 0.09 (‐0.02 ‐ 0.22) 0.15 0.09 ‐0.04 ‐ 0.33 1.58 0.114
UKBB_p3 1,280,135 2,658         15,238        17,896 0.14 0.05 0.04 ‐ 0.24 0.20 0.07 (0.04 ‐ 0.24) 0.21 0.08 0.06 ‐ 0.37 2.75 6.0 x 10‐3
Women UKBB_p1 1,160,174 6,845 64,099 70,944 0.14 0.02 0.1 ‐ 0.18 0.19 0.03 (0.1 ‐ 0.18) 0.21 0.03 0.14 ‐ 0.27 6.36 2.0 x 10‐10
UKBB_p2 1,280,135 4,389 28,545 32,934 0.08 0.03 0.02 ‐ 0.14 0.11 0.04 (0.02 ‐ 0.14) 0.12 0.05 0.03 ‐ 0.21 2.66 7.8 x 10‐3
UKBB_p3 1,280,135 4,389 11,697 16,086 0.17 0.04 0.1 ‐ 0.24 0.23 0.05 (0.1 ‐ 0.24) 0.25 0.05 0.14 ‐ 0.36 4.61 4.0 x 10‐6
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PGC1.5 PGC2 studies not including the UK Biobank; here only subjects of European ancestry are included, UKB UK Biobank subjects 
of European ancestry 
rg genetic correlation, SE standard error, z test-statistic, N/A fails to run, * p > 0.05 
 
Subset 1 Subset 2
Subset 1 Subset 2 N  SNPs N  cases N  controls h 2 SNP SE N cases N  controls h
2
SNP SE r g SE z p ‐value
PGC1.5 smal PGC1.5 large 1,154,022 2,102 7,366 0.12 0.06 10,721 28,282 0.03 0.00 0.45 0.26 1.71 0.087
UKB w UKB m 1,160,174 6,845 64,099 0.19 0.03 3,544 51,700 0.15 0.05 1.03 0.24 4.31 1.6 x 10‐5
PGC1.5 w PGC1.5 m 1,162,530 6,128 9,528 0.21 0.05 6,364 23,905 0.01* 0.03 N/A N/A N/A N/A
PGC1.5 w  UKB 1,157,449 6,128 9,528 0.21 0.05 10,389 115,799 0.18 0.02 0.46 0.13 3.56 4.0 x 10‐4
PGC1.5 w UKB w 1,164,765 6,128 9,528 0.21 0.05 6,845 64,099 0.19 0.03 0.46 0.14 3.34 8.0 x 10‐4
PGC1.5 w UKB m 1,158,070 6,128 9,528 0.21 0.05 3,544 51,700 0.15 0.05 0.44 0.23 1.94 0.052
PGC1.5 m UKB m 1,159,417 6,364 23,905 0.01* 0.03 3,544 51,700 0.15 0.05 N/A N/A N/A 0.70
PGC1.5 m UKB w 1,158,070 6,364 23,905 0.01* 0.03 6,845 64,099 0.19 0.03 N/A N/A N/A N/A
PGC1.5 UKB 1,175,791 12,823 35,648 0.05 0.02 10,389 115,799 0.18 0.02 0.73 0.21 3.50 0.0005
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Supplementary Table 3 Description of European ancestry (EUA) meta-analysis 




N/A not enough subjects for analysis 
*linear mixed models in GEMMA to account for relatedness 
**linear regression in BGenie v1.2  
N  subjects Males Females N  total
Study No. abbrev. cases controls cases controls cases controls
1 MRSC 310               2,199           304 2,197 N/A N/A 2,509         
2 ONGA 118               102               88 82 N/A N/A 220             
5 NHS2 579               741               N/A N/A 579 741 1,320         
6 GSDC 263               1,227           100 785 163 442 1,490         
7 FSCD 111               436               45 230 66 206 547             
9 COGA 49                 894               N/A N/A N/A N/A 943             
9 COGB 49                 815               N/A N/A N/A N/A 864             
10 BRYA 87                 572               41 350 46 222 659             
13 NHRV 156               2,136           119 1,967 37 169 2,292         
14 NSS1 1,264           3,586           1,028 3,148 236 438 4,850         
15 NSS2 909               949               752 784 157 165 1,858         
16 PPDS 677               4,295           637 4,116 39 164 4,972         
17 KSUD 121               96                 57 72 47 20 217             
18 BOBA 70                 68                 25 24 45 44 138             
21 GUTS 261               255               70 67 191 188 516             
22 NHSY 2,652           2,611           N/A N/A 2,652 2,611 5,263         
24 VETS* 85                 1,114           85 1,114 N/A N/A 1,199         
25 PRIS 113               706               100 642 N/A N/A 819             
26 MIRE 418               405               343 343 75 62 823             
27 INTR 78                 116               69 55 N/A N/A 194             
28 DAMI 462               2,019           407 1,919 55 100 2,481         
29 DAIP 666               2,721           208 847 458 1,874 3,387         
30 QIMR* 325               1,797           101 934 224 863 2,122         
31 NCPT 299               162               215 84 84 78 461             
32 TRAC 148               49                 131 49 N/A N/A 197             
33 RING 35                 156               35 151 N/A N/A 191             
35 STRO 320               1,926           298 1,829 N/A N/A 2,246         
36 BRY2 68                 56                 N/A N/A 40 30 124             
41 NCMH 622               622               234 235 388 387 1,244         
42 EACR 67                 231               N/A N/A 41 168 298             
43 WACH 56                 56                 N/A N/A 56 56 112             
47 GTPC 80                 107               N/A N/A 61 58 187             
48 BETR 46                 53                 45 53 0 0 99               
49 SEEP 306               325               204 223 102 102 631             
50 COM1 75                 134               70 122 0 0 209             
52 FTCB 85                 953               80 911 0 0 1,038         
54 GRAC 76                 92                 N/A N/A 76 92 168             
55 GALI 100               123               100 123 N/A N/A 223             
60 UKB** 10,389         115,799       3,544           51,700         6,845           64,099         126,188     
11_12 MINV 145               96                 142 88 N/A N/A 241             
19‐20 PSY1 62                 86                 N/A N/A 45 51 148             
37‐40 PSY3 232               306               64 109 165 197 538             
56‐59 WRBY 178               255               167 252 N/A N/A 433             
23,212         151,447       9,908         75,605       12,973       73,627        174,659     Meta‐analysis
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A1 allele 1 (coded allele), A2 allele2, A1 freq A1 allele frequency 
* z-test on differences between effect sizes (Beta) of male and female meta-analyses 
 
Variant Studies A1 A2 Sex A1 freq Beta SE OR P ‐value N cases N controls N effective p ‐sex difference*
rs34517852 EUA both a t both 0.341 0.110 0.019 1.12 3.2 x 10‐9 12,080        33,446       30,274      
male 0.344 0.113 0.025 1.12 7.5 x 10‐6 5,920          22,628       16,278       0.80
female 0.339 0.104 0.029 1.11 2.8 x 10‐4 5,829          8,603         12,906      
rs9364611 EUA both t c both 0.131 ‐0.124 0.023 0.88 4.4 x 10‐8 23,212        151,447     70,332      
male 0.132 ‐0.109 0.032 0.90 6.3 x 10‐4 9,908          75,605       30,595       0.51
female 0.131 ‐0.139 0.034 0.87 3.3 x 10‐5 12,973        73,627       38,491      
rs115539978AFA both t c both 0.074 0.284 0.051 1.33 2.8 x 10‐8 4,363          10,976       11,322      
male 0.073 0.279 0.079 1.32 4.3 x 10‐4 1,782          5,361         4,702         0.68
female 0.075 0.323 0.070 1.38 4.0 x 10‐6 2,360          4,926         6,064        
rs571848662EUA m t tatac both 0.608 ‐0.083 0.018 0.92 2.8 x 10‐6 12,498        33,851       31,097      
male 0.608 ‐0.139 0.024 0.87 7.9 x 10‐9 6,263          22,971       16,964       8.4 x 10‐4
female 0.607 ‐0.017 0.027 0.98 0.530 5,904           8,665           13,042        
rs148757321EUA m ctgtg c both 0.827 0.091 0.022 1.10 3.2 x 10‐5 12,498        33,851       31,097      
male 0.828 0.168 0.031 1.18 3.8 x 10‐8 6,263          22,971       16,964       9.6 x 10‐4
female 0.826 0.018 0.034 1.02 0.590 5,904           8,665           13,042        
rs142174523AFA m a g both 0.305 ‐0.122 0.031 0.89 1.0 x 10‐4 4,363          10,976       11,322      
male 0.300 ‐0.277 0.051 0.76 4.3 x 10‐8 1,782          5,361         4,702         9.9 x 10‐5
female 0.307 ‐0.021 0.042 0.98 0.620 2,360           4,926           6,064          
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Supplementary Table 5 Description of African ancestry (AFA) meta-analysis of 




N/A not enough subjects for analysis 
  
N  subjects Males Females N total
Study No. abbrev. cases controls cases controls cases controls
1 MRSC 39              193            39              193            N/A N/A 232         
3 SAFR 77              139            N/A N/A 77              139            216         
4 DNHS 155            481            52              208            103            273            636         
6 GSDC 350            2,140        168            1,201        182            939            2,490      
7 FSCD 159            441            71              230            88              211            600         
9 COGB 37              359            N/A N/A N/A N/A 396         
14 NSS1 328            1,107        210            825            118            282            1,435      
15 NSS2 202            223            129            154            73              69              425         
16 PPDS 107            852            92              750            N/A N/A 959         
26 MIRE 566            544            378            381            188            163            1,110      
31 NCPT 40              32              30              23              N/A N/A 72            
35 STRO 98              518            80              425            N/A N/A 616         
43 WACH 78              72              N/A N/A 78              72              150         
45 ADNH 50              47              N/A N/A N/A N/A 97            
47 GTPC 1,546        3,412        371            902            1,175        2,510        4,958      
50 COM1 30              40              N/A N/A N/A N/A 70            
54 GRAC 52              33              N/A N/A 52              33              85            
17‐20 PSY1 63              57              N/A N/A 32              30              120         
37‐40 PSY3 140            66              64              16              73              50              206         
56‐59 WRBY 117            58              98              53              N/A N/A 175         
44 EGHS 129            162            N/A N/A 121            155            291         
4,363        10,976      1,782        5,361        2,360        4,926        15,339   Meta‐analysis
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Supplementary Table 6 Description of American ancestry (AMA) meta-analysis 




N/A not enough subjects for analysis 
 
N  subjects Males Females N  total
Study No. abbrev. cases controls cases controls cases controls
1 MRSC 83              535            81              533            N/A N/A 618         
14 NSS1 128            499            97              422            N/A N/A 627         
15 NSS2 106            127            83              101            23              26              233         
16 PPDS 85              677            72              634            N/A N/A 762         
23 PROM 1,508        1,526        N/A N/A 1,508        1,526        3,034      
35 STRO 71              358            67              322            N/A N/A 429         
1,981        3,722        400            2,012        1,531        1,552        5,703      Meta‐analysis
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*subjects with haplotypes of different ancestry are counted twice 
  
Description of allele frequencies stratified by copies and type of ancestral haplotypes
Ancestal background A1 A2 A1 freq N* case N* Control N* total
1 European  t c 0.008 953 2,788 3,741
2 European  t c 0.003 152 447 599
1 African  t c 0.080 1,025 2,945 3,970
2 African  t c 0.089 2,556 6,960 9,516
1 Native American  t c 0.008 100 253 353
2 Native American  t c 0 0 2 2
Comparison of SNP association with PTSD including 5 global PC's versus local ancestry inference (LAI) in the analysis
Model A1 A2 A1 freq OR SE P ‐value N cases N controls N  total
SNP effect (with 5 global PCs) t c 0.072 1.31 0.052 2.4 x 10‐7 3,747 10,402 14,149
SNP effect (with LAI + 5 global PC t c 0.072 1.30 0.053 7.1 x 10‐7 3,747 10,402 14,149
PTSD predicted by copies of  A1 allele on specific ancestral background
Ancestral background A1 A2 OR SE P ‐value
European t c 0.70 0.462 0.44
African t c 1.32 0.053 9.6 x 10‐8
Native American t c 0.00 112.271 0.93
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*subjects with haplotypes of different ancestry are counted twice 
  
Description of allele frequencies stratified by copies and type of ancestral haplotypes
Ancestal background A1 A2 A1 freq N* case N* Control N* total
1 European  a g 0.25 419 1,358 1,777
2 European  a g 0.23 70 206 276
1 African  a g 0.34 453 1,526 1,979
2 African  a g 0.32 821 3,150 3,971
1 Native American  a g 0.40 80 312 392
2 Native American  a g 0.29 6 8 14
Comparison of SNP association with PTSD including 5 global PC's versus local ancestry inference (LAI) in the analysis
Model A1 A2 A1 freq OR SE P ‐value N cases N controls N total
SNP effect (with 5 global PCs) a g 0.31 0.80 0.051 8.0 x 10‐6 1,373         4,962         6,335
SNP effect (with LAI + 5 global PC a g 0.31 0.80 0.051 1.4 x 10‐5 1,373         4,962         6,335
PTSD predicted by copies of  A1 allele on specific ancestral background
Ancestral background A1 A2 OR SE P ‐value
European a g 0.80 0.115 0.055
African a g 0.79 0.055 2.2 x 10‐5
Native American a g 0.89 0.215 0.57
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The MVP GWAS is on re-experiencing symptoms, a core feature of PTSD 
 
A1 allele 1 (coded allele), A2 allele2, A1 freq A1 allele frequency, LD Linkage Disequilibrium estimate with variant 
* Replication (MVP): no sex-stratified analyses available; cohort is predominantly male 
** If variant was not genotyped in MVP, an LD proxy variant was used instead. LD between variant and proxy is noted in parenthesis 
† N subjects number of MVP subjects with re-experiencing symptoms phenotype (REX) 
  
Subjects (original finding) Replication (MVP)* Variant Replication Variant (LD)** Chr Position (bp) A1 A2 A1 freq Beta SE P ‐value N subjects†
European ancestry
all all rs34517852 rs34517852 6 157789333 a t 0.342 0.0002 0.018 0.990 146,660       
all all rs9364611 rs9364611 6 162163506 t c 0.130 ‐0.027 0.025 0.264 146,660       
male all (6.6% female) rs571848662 rs8112292 (0.75) 19 53988841 t c 0.468 0.005 0.017 0.782 146,660       
male all (6.6% female) rs148757321 rs148757321 1 15436223 ctgtg c 0.829 0.024 0.022 0.274 146,660       
African ancestry
all all rs115539978 rs115539978 13 55759209 t c 0.071 ‐0.119 0.112 0.289 19,983         
male all rs142174523 rs9265461 (0.77) 6 31294290 a g 0.361 0.011 0.064 0.857 19,983         
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Leading markers for genome-wide significant loci (at p<5x10-8) in the overall and sex-stratified analyses are reported. 
 
A1 allele 1 (coded allele), A2 allele2, A1 freq A1 allele frequency, Beta_cojo Beta value conditioned on summary data from the PGC-
PTSD major depressive disorder (MDD) GWAS, using multi-trait conditional and joint analysis  (mtCOJO), OR_cojo Odds ratio 
conditioned on PGC-PTSD MDD, SE_cojo Standard error of beta conditioned on PGC-PTSD MDD, P_cojo p-value of beta 
conditioned on PGC-PTSD MDD 
*rs571848662 is not in MDD data 
** rs8112292 is the proxy SNP in highest LD (r2 = 0.85 in 1000G CEU) with rs571848662 
  
Subjects Variant Chr Position (bp) A1 A2 A1 freq Beta SE OR P ‐value Beta_cojo SE_cojo OR_cojo P_cojo N cases N controls
EUA all rs34517852 6 157789333 a t 0.341 0.110 0.019 1.12 3.2 x 10‐9 0.112 0.019 1.12 1.8 x 10‐9 12,080   33,446  
EUA all rs9364611 6 162163506 t c 0.131 ‐0.124 0.023 0.88 4.4 x 10‐8 ‐0.128 0.023 0.88 1.7 x 10‐8 23,212     151,447  
EUA male rs571848662* 19 53988841 t tatac 0.608 ‐0.139 0.024 0.87 7.9 x 10‐9 NA* NA NA NA 6,263      22,971  
EUA male rs8112292** 19 53989669 t c 0.464 0.096 0.022 1.10 1.0 x 10‐5 0.092 0.022 1.10 2.1 x 10‐5 9,799      74,615  
EUA male rs148757321 1 15436223 ctgtg c 0.828 0.168 0.031 1.18 3.8 x 10‐8 0.180 0.031 1.20 5.5 x 10‐9 6,263      22,971  
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Leading markers for genome-wide significant loci (at p<5x10-8) in the overall and sex-stratified analyses are reported. 
 
A1 allele 1 (coded allele), A2 allele2, A1 freq A1 allele frequency, Beta_cojo Beta value conditioned on summary data from the PGC-
PTSD bipolar disorder (BPD), major depressive disorder (MDD) and schizophrenia (SCZ) GWAS, using multi-trait conditional and joint 
analysis  (mtCOJO), OR_cojo Odds ratio conditioned on BPD, MDD and SCZ, SE_cojo Standard error of beta conditioned on BPD, 
MDD and SCZ, P_cojo p-value of beta conditioned on BPD, MDD and SCZ 
*rs571848662 is not in in all summary statistic datasets 
** rs8112292 is the proxy SNP in highest LD  (r2=0.85 in 1000G CEU) with rs571848662 
***rs148757321 is not in all summary statistic datasets 
**** rs518152 is the proxy SNP  in highest LD (r2=0.96 in 1000G CEU) with rs148757321 
 
  
Subjects Variant Chr Position (bp) A1 A2 A1 freq Beta SE OR P ‐value Beta_cojo SE_cojo OR_cojo P_cojo N cases N controls
EUA all rs34517852 6 157789333 a t 0.341 0.110 0.019 1.12 3.2 x 10‐9 0.115 0.019 1.12 1.1 x 10‐9 12,080   33,446  
EUA all rs9364611 6 162163506 t c 0.131 ‐0.124 0.023 0.88 4.4 x 10‐8 ‐0.132 0.023 0.88 9.7  x 10‐9 23,212     151,447  
EUA male rs571848662* 19 53988841 t tatac 0.608 ‐0.139 0.024 0.87 7.9 x 10‐9 NA* NA NA NA 6,263      22,971  
EUA male rs8112292** 19 53989669 t c 0.464 0.096 0.022 1.10 1.0 x 10‐5 0.080 0.022 1.08 3.9 x 10‐4 9,799      74,615  
EUA male rs148757321*** 1 15436223 ctgtg c 0.828 0.168 0.031 1.18 3.8 x 10‐8 NA*** NA NA NA 6,263      22,971  
EUA male rs518152**** 1 15434259 a g 0.171 ‐0.146 0.029 0.86 3.4 x 10‐7 ‐0.146 0.030 0.86 8.6 x 10‐7 9,900      75,549  
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* only subjects with available individual-level genotype data are included here 
 
 
Ancestry grouping N cases* N controls* N total* % total GWAS grouping
Continental regions:
Africa 82             151              233              0.34 African ancestry (AFA)
Europe 10,643    28,633        39,276        56.53 European ancestry (EUA)
Central/South Asia 8               62                70                0.10 excluded
East Asia 92             436              528              0.76 excluded
Americas 642          679              1,321          1.90 American ancestry (AMA)
Oceania 15             75                90                0.13 excluded
Mixed ancestry:
Africa/Europe (mostly African American) 4,428       12,456        16,884        24.30 African ancestry (AFA)
Americas/Europe (mostly Latinos) 1,544       3,486          5,030          7.24 American ancestry (AMA)
East Asia/Europe (mostly Filipinos) 58             212              270              0.39 excluded
Europe/Americas/Africa (mostly Puerto Rican) 303          1,163          1,466          2.11 excluded
Others 1,125       3,191          4,316          6.21 excluded
Total 18,940    50,544        69,484        100
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All populations belong to the AFR super population 
 
*genotype for rs115539978, T: minor allele, C: major allele 
**Population abbreviations: ACB African Caribbeans in Barbados, ASW Americans of 
African Ancestry in SW USA, ESN Esan in Nigeria, GWD Gambian in Western 
Divisions in the Gambia, LWK Luhya in Webuye, Kenya, MSL Mende in Sierra Leone 
  
Cell Line Genotype* Gender Population**
HG02545 T/T M ACB
HG03376 T/T M MSL
GM20281 T/T M ASW
HG02703 T/T F GWD
HG03114 T/T F ESN
GM19351 T/T F LWK
HG01879 C/C M ACB
HG03057 C/C M MSL
GM19700 C/C M ASW
HG02462 C/C F GWD
HG02922 C/C F ESN
GM19017 C/C F LWK
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Supplementary Table 14 Primers used for functional follow-up of rs115539978 
 
 
 
 
Primer Name Sequence 5'‐3'
uc_338‐fwd1 TCCCATCTGCTCAAACCACT
uc_338‐rev1 CCTCTCAAGAGAAAGACAAAGG
Linc02335ex1ex2‐fwd1 GCCACTGCTTTCAGCCTTTA
Linc02335ex1ex2‐rev1     ATCAGTCTTTCTCAGGAAGTAGACA
Linc00558fwd1    CTCCGCTAACACACACTTTCA
Linc00558rev1    CCATCCTTTTACTTCCAGCCTA
Linc00458fwd1 ACAGTCCTCAGCCTCCTGAA
Linc00458rev1 TGGGTTGGTGTTCTCCTCTC
hsaGAPDHfwd AGCTCAGGGATGACCTTGC
hsaGAPDHfwd TCACTGCCACCCAGAAGACT
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